<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004721" GROUP_ID="PROSTATE" ID="425701091521413405" MERGED_FROM="" MODIFIED="2011-04-05 16:24:51 +0200" MODIFIED_BY="James Tacklind" REVIEW_NO="4" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2011-04-05 16:24:51 +0200" MODIFIED_BY="James Tacklind">
<TITLE>Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy</TITLE>
<CONTACT MODIFIED="2011-04-05 16:24:51 +0200" MODIFIED_BY="James Tacklind"><PERSON ID="17134" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Wai Man</FIRST_NAME><LAST_NAME>Sze</LAST_NAME><EMAIL_1>szewm@netvigator.com</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Oncology</DEPARTMENT><ORGANISATION>Pamela Youde Nethersole Eastern Hospital</ORGANISATION><ADDRESS_1>LG1 East Block</ADDRESS_1><ADDRESS_2>3 Lok Man Road</ADDRESS_2><CITY>Hong Kong</CITY><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>852-25954175</PHONE_1><FAX_1>852-25151266</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-04-05 16:24:51 +0200" MODIFIED_BY="James Tacklind"><PERSON ID="17134" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Wai Man</FIRST_NAME><LAST_NAME>Sze</LAST_NAME><EMAIL_1>szewm@netvigator.com</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Oncology</DEPARTMENT><ORGANISATION>Pamela Youde Nethersole Eastern Hospital</ORGANISATION><ADDRESS_1>LG1 East Block</ADDRESS_1><ADDRESS_2>3 Lok Man Road</ADDRESS_2><CITY>Hong Kong</CITY><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>852-25954175</PHONE_1><FAX_1>852-25151266</FAX_1></ADDRESS></PERSON><PERSON ID="16073" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mike</FIRST_NAME><LAST_NAME>Shelley</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Senior Clinical Scientist</POSITION><EMAIL_1>mike.shelley@velindre-tr.wales.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Prostatic Diseases and Urological Cancers Unit, Research Dept</DEPARTMENT><ORGANISATION>Velindre NHS Trust</ORGANISATION><ADDRESS_1>Velindre Road</ADDRESS_1><ADDRESS_2>Whitchurch</ADDRESS_2><CITY>Cardiff</CITY><ZIP>CF4 7XL</ZIP><REGION>Wales</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 022 261 5888</PHONE_1><PHONE_2>+44 292 031 6909</PHONE_2><FAX_1>+44 022 252 9625</FAX_1></ADDRESS></PERSON><PERSON ID="E465D74482E26AA201E74FE90C407704" ROLE="AUTHOR"><FIRST_NAME>Ines</FIRST_NAME><LAST_NAME>Held</LAST_NAME><ADDRESS><DEPARTMENT>Nephrology</DEPARTMENT><ORGANISATION>Cardiff University and North East Wales NHS Trust</ORGANISATION><CITY>Cardiff</CITY><REGION>Wrexham</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16377" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Malcolm</FIRST_NAME><LAST_NAME>Mason</LAST_NAME><POSITION>Professor of Clinical Oncology</POSITION><EMAIL_1>malcolm.mason@velindre-tr.wales.nhs.uk</EMAIL_1><EMAIL_2>masonmd@cardiff.co.uk</EMAIL_2><ADDRESS><DEPARTMENT>Clinical Oncology</DEPARTMENT><ORGANISATION>Velindre Hospital</ORGANISATION><ADDRESS_1>Whitchurch</ADDRESS_1><CITY>Cardiff</CITY><ZIP>CF4 7XL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1222 615888</PHONE_1><FAX_1>+44 1222 522694</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-05-28 12:39:50 -0500" MODIFIED_BY="Jim Tacklind" NOTES="&lt;p&gt;Minor update: 9/9/02&lt;/p&gt;" NOTES_MODIFIED="2008-05-28 12:39:50 -0500" NOTES_MODIFIED_BY="Jim Tacklind">
<UP_TO_DATE>
<DATE DAY="15" MONTH="9" YEAR="2001"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="9" YEAR="2001"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2011-04-05 09:23:32 -0500" MODIFIED_BY="James Tacklind">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-04-05 09:23:32 -0500" MODIFIED_BY="James Tacklind">
<DATE DAY="5" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>The primary author has indicated he will not be updating this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-04-05 09:23:19 -0500" MODIFIED_BY="James Tacklind">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-04-05 09:23:19 -0500" MODIFIED_BY="James Tacklind">
<DATE DAY="28" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="9" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital</NAME>
<COUNTRY CODE="HK">Hong Kong</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Velindre NHS Trust, Cardiff</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-04-05 09:23:07 -0500" MODIFIED_BY="James Tacklind">
<SUMMARY MODIFIED="2008-05-29 07:46:25 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-29 07:46:25 -0500" MODIFIED_BY="[Empty name]">Easing of bone pain caused by metastatic cancer: single versus multifraction radiotherapy</TITLE>
<SUMMARY_BODY MODIFIED="2008-05-28 12:40:48 -0500" MODIFIED_BY="[Empty name]">
<P>The spread of tumour to the bone (metastasis) is a common characteristic of many malignancies including cancers of the prostate, breast and lung. This may be associated with pain, compression of the spinal cord and the potential for bone fracture. Radiotherapy is used to treat bone metastases, however, the optimum treatment schedule is unclear. This review compares whether a single fraction of radiotherapy is better than multifractions of radiotherapy for alleviating the symptoms associated with tumours that have spread to the bone. Eleven randomised trials were identified in the published literature that compared single versus multifraction radiotherapy for bone metastases. Pooled analysis of these trials suggested that single fraction radiotherapy was as effective as multifraction radiotherapy in controlling bone pain. However, there were more bone fractures in patients treated by single fraction radiotherapy, and they received further treatment sessions more often than those receiving multifraction radiotherapy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-28 13:05:26 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-05-28 12:42:06 -0500" MODIFIED_BY="[Empty name]">
<P>Recent randomised studies reported that single fraction radiotherapy was as effective as multifraction radiotherapy in relieving pain due to bone metastasis. However, there are concerns about the higher retreatment rates and the efficacy of preventing future complications such as pathological fracture and spinal cord compression by single fraction radiotherapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To undertake a systematic review and meta-analysis of single fraction radiotherapy versus multifraction radiotherapy for metastatic bone pain relief and prevention of bone complications. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Trials were identified through MEDLINE, EMBASE, Cancerlit, reference lists of relevant articles and conference proceedings. Relevant data was extracted. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised studies comparing single fraction radiotherapy with multifraction radiotherapy on metastatic bone pain</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The analyses were performed using intention-to-treat principle. The results were pooled using meta-analysis to estimate the effect of treatment on pain response, re-treatment rate, pathological fracture rate and spinal cord compression rate. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-28 13:05:26 -0500" MODIFIED_BY="[Empty name]">
<P>Eleven trials that involved 3435 patients were identified. Of 3435 patients, 52 patients were randomised more than once for different painful bone metastasis sites. Altogether, 3487 painful sites were randomised. The trials included patients with painful bone metastases of any primary sites, but were mainly prostate, breast and lung. The overall pain response rates for single fraction radiotherapy and multifraction radiotherapy were 60% (1059/1779) and 59% (1038/1769) respectively, giving an odds ratio of 1.03 (95% confidence interval [CI], 0.89 to 1.19) indicating no difference between the two radiotherapy schedules. There was also no difference in complete pain response rates for single fraction radiotherapy (34% [497/1441]) and multifraction radiotherapy (32% [463/1435]) with an odds ratio of 1.11 (95% CI 0.94 to 1.30). Patients treated by single fraction radiotherapy had a higher re-treatment rate with 21.5% (267/1240) requiring re-treatment compared to 7.4% (91/1236) of patients in the multifraction radiotherapy arm (odds ratio 3.44 [95% CI 2.67 to 4.43]). The pathological fracture rate was also higher in single fraction radiotherapy arm patients. Three percent (37/1240) of patients treated by single fraction radiotherapy developed pathological fracture compared to 1.6% (20/1236) for those treated by multifraction radiotherapy (odds ratio 1.82 [95% CI 1.06 to 3.11]). The spinal cord compression rates were similar for both arms (odds ratio 1.41 [95% CI 0.72 to 2.75]). Repeated analyses excluding dropout patients gave similar results.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-05-28 12:43:58 -0500" MODIFIED_BY="[Empty name]">
<P>Single fraction radiotherapy was as effective as multifraction radiotherapy in relieving metastatic bone pain. However, the retreatment rate and pathological fracture rates were higher after single fraction radiotherapy. Studies with quality of life and health economic end points are warranted to find out the optimal treatment option.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-28 13:26:42 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-05-28 13:04:49 -0500" MODIFIED_BY="[Empty name]">
<P>Bone metastasis is a common occurrence in the event of malignancy (<LINK REF="REF-Porter-1994" TYPE="REFERENCE">Porter 1994</LINK>) and is the third commonest site of distant metastases after liver and lung (<LINK REF="REF-Brown-2001" TYPE="REFERENCE">Brown 2001</LINK>). Although some bone metastases are painless, many frequently cause significant and debilitating pain (<LINK REF="REF-Janjan-1998" TYPE="REFERENCE">Janjan 1998</LINK>). Besides bone pain, bone metastases can also give rise to pathological fracture (<LINK REF="REF-Bunting-2001" TYPE="REFERENCE">Bunting 2001</LINK>) and spinal cord compression, which result in significant morbidities. Treatment for bone metastasis often requires a multimodality approach, the main aims of which are to palliate pain and prevent future complications (<LINK REF="REF-Bates-1992a" TYPE="REFERENCE">Bates 1992a</LINK>).</P>
<P>Radiotherapy is a frequently used modality for bone metastasis and has been shown to be effective in decreasing metastatic bone pain (<LINK REF="REF-McQuay-2001" TYPE="REFERENCE">McQuay 2001</LINK>) and causing tumour shrinkage or growth inhibition. Radiotherapy is usually given as an outpatient treatment, however, it requires daily hospital attendance, usually at a specialised centre that may be some distance away from patient's home. If the course of radiotherapy is protracted, it may cause considerable problems for the patient, especially those with poor performance status and limited life expectancy. From a health economic point of view, radiotherapy for bone pain constitutes a significant workload of a radiotherapy centre (<LINK REF="REF-Crellin-1989" TYPE="REFERENCE">Crellin 1989</LINK>). It is, therefore, important to strike a balance between the treatment efficacy, patient convenience and cost (<LINK REF="REF-Macklis-1998" TYPE="REFERENCE">Macklis 1998;</LINK> <LINK REF="REF-Lievens-Y-2000" TYPE="REFERENCE">Lievens Y 2000</LINK>).</P>
<P>There is yet no consensus regarding the most appropriate way of delivering radiotherapy for metastatic bone pain (<LINK REF="REF-Bates-1992b" TYPE="REFERENCE">Bates 1992b</LINK>; <LINK REF="REF-Rose-1998" TYPE="REFERENCE">Rose 1998</LINK>; <LINK REF="REF-Hoskin--2001b" TYPE="REFERENCE">Hoskin 2001b</LINK>; <LINK REF="REF-Chander-1999" TYPE="REFERENCE">Chander 1999</LINK>). The practice differs significantly among different countries (<LINK REF="REF-Maher-1992" TYPE="REFERENCE">Maher 1992</LINK>; <LINK REF="REF-Lievens-2000" TYPE="REFERENCE">Lievens 2000</LINK>) and,indeed, between different treatment centres within the same country (<LINK REF="REF-Crellin-1989" TYPE="REFERENCE">Crellin 1989</LINK>; <LINK REF="REF-Priestman-1989" TYPE="REFERENCE">Priestman 1989</LINK>; <LINK REF="REF-Ben_x002d_Josef-1998" TYPE="REFERENCE">Ben-Josef 1998</LINK>; <LINK REF="REF-Lawton-1991" TYPE="REFERENCE">Lawton 1991</LINK>; <LINK REF="REF-Duncan-1993" TYPE="REFERENCE">Duncan 1993</LINK>; <LINK REF="REF-Stevens-1995" TYPE="REFERENCE">Stevens 1995</LINK>; <LINK REF="REF-Chow-2000" TYPE="REFERENCE">Chow 2000</LINK>; <LINK REF="REF-Roos--2000a" TYPE="REFERENCE">Roos 2000a</LINK>). One of the controversies, is whether single fraction radiotherapy is as effective as multifraction radiotherapy. Single fraction radiotherapy is more convenient for the patient and it is also less costly compared to multifraction radiotherapy. However, there are some important concerns relating to single fraction radiotherapy. The equivalent biological dose of single fraction treatment is usually smaller compared to multifraction treatment. As a result, the pain response may be inferior to multifraction radiotherapy (<LINK REF="REF-Ben_x002d_Josef-1999" TYPE="REFERENCE">Ben-Josef 1999</LINK>; <LINK REF="REF-Ratanatharathorn--1999" TYPE="REFERENCE">Ratanatharathorn 1999</LINK>). Even if the initial pain response is similar, it may not be durable enough to ensure that the patient remains asymptomatic. In addition, with a potentially reduced tumoricidal effect, single fraction radiotherapy may not be as effective in preventing complications, such as pathological fracture (<LINK REF="STD-Koswig-1999" TYPE="STUDY">Koswig 1999</LINK>) and spinal cord compression.</P>
</BACKGROUND>
<OBJECTIVES>
<P>Although there are a number of published studies comparing single fraction treatment to multifraction treatment, consensus is still lacking. The purpose of this systematic review is to assess the efficacy of single fraction radiotherapy against multifraction radiotherapy in relieving metastatic bone pain and preventing pathological fracture and spinal cord compression.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-05-28 13:16:31 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-05-28 12:41:06 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Published randomized, controlled trials. Published abstracts were included but unpublished studies were not sought. Studies published in any language were also eligible if they fulfilled the inclusion criteria. No authors were contacted for clarification or verification of patient data. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with painful bone metastases from any primary tumour</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Single fraction external radiotherapy versus multifraction external radiotherapy. Studies of pain relief comparing radioisotopes or drugs were excluded. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-05-28 12:41:06 -0500" MODIFIED_BY="[Empty name]">
<P>The studies included must have at least one pain outcome assessment. All types of pain outcome assessment were allowed. Other outcome measures include the retreatment rate and frequency of pathological fracture and spinal cord compression. The pain response criteria follow the definition of the individual study. In general, complete pain response was defined as no pain and any pain relief was defined as lesser degree of pain compared to the pre-treatment level. However, there are variations among different studies regarding the pain assessment tool, timing in assessing the pain response and whether use of analgesic was used as part of criteria in pain evaluation. The different criteria are summarised in the table of characteristics of included studies.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-28 13:13:56 -0500" MODIFIED_BY="[Empty name]">
<P>An electronic search of several major medical and scientific databases was undertaken and include the following with dates: Medline (1966 to November 2001), Embase (1980 to November, 2001), CancerLit (1975 to October 2001) and the Controlled Trials Register on the Cochrane Library. The exact search strategy* used was shown as below:</P>
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>Randomized controlled trials/</LI>
<LI>Random allocation/</LI>
<LI>Double blind method/</LI>
<LI>Single blind method/</LI>
<LI>clinical trial.pt.</LI>
<LI>exp Clinical trials/</LI>
<LI>(clin$ adj25 trial$).tw.</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.</LI>
<LI>Placebos/</LI>
<LI>placebos.tw.</LI>
<LI>random.tw.</LI>
<LI>Research design/</LI>
<LI>Comparative study/</LI>
<LI>exp Evaluation studies/</LI>
<LI>Follow up studies/</LI>
<LI>Prospective studies/</LI>
<LI>(control$ or prospectiv$ or volunteer$).tw.</LI>
<LI>or/1-19</LI>
<LI>limit 20 to animal</LI>
<LI>limit 20 to human</LI>
<LI>21 and 22</LI>
<LI>21 not 23</LI>
<LI>20 not 24</LI>
<LI>exp Bone Neoplasms/</LI>
<LI>Osseous metastasis or Osseous metastases</LI>
<LI>26 or 27</LI>
<LI>25 and 28</LI>
<LI>(radiotherapy or irradiation or radiation).mp. [mp=title, abstract, registry number word, mesh subject heading]</LI>
<LI>29 and 30</LI>
<LI>(pain or "analges*").mp. [mp=title, abstract, registry number word, mesh subject heading]</LI>
<LI>31 and 32</LI>
</OL>
<P>
<BR/>
</P>
<P>All the searched abstracts were screened for relevance. Eligible published studies were also identified from reference lists of retrieved paper, textbooks and review articles. A number of conference proceedings were hand searched for meeting abstract. A number of specific journals were hand searched up to June 2002, including <I>British Journal of Cancer</I>, <I>Journal of the National Cancer Institute</I>, <I>European Journal of Cancer</I>, <I>Journal of Clinical Oncology</I>, <I>The Lancet Oncology</I>, <I>Cancer and Journal of Pain and Symptom Management</I>. The selection of studies for inclusion was carried out independently by WM Sze and M Shelley.</P>
<P>*NB: The main structure of the search strategy was adapted from the generic search strategy for randomised studies designed by librarians at the Hospital Authority of Hong Kong</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-28 13:16:31 -0500" MODIFIED_BY="[Empty name]">
<P>The following information was extracted from each relevant article:</P>
<OL>
<LI>Patient eligibility criteria</LI>
<LI>Number of patients</LI>
<LI>Radiotherapy fractionation - dose per fraction and number of fractions</LI>
<LI>Pain assessment tools or methods</LI>
<LI>Pain assessment schedule</LI>
<LI>Proportion of missing data of pain evaluation</LI>
<LI>Efficacy:</LI>
<OL>
<LI>Overall pain response</LI>
<LI>Complete pain response</LI>
<LI>Retreatment rate</LI>
<LI>Pathological fracture rate</LI>
<LI>Spinal cord compression rate</LI>
</OL>
</OL>
<P>
<BR/>
</P>
<P>The data analyses were made with Review Manager v4.1 supplied by The Cochrane Collaboration. The statistical methods were detailed in the statistical manual of MetaView Version 4 (<LINK REF="REF-Deeks-1999" TYPE="REFERENCE">Deeks 1999</LINK>). The odds ratio and 95% confidence interval were calculated for each trial and presented in a Forrest plot.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-05-28 13:24:22 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-05-28 13:16:54 -0500" MODIFIED_BY="[Empty name]">
<P>Thirty-one studies were identified as potential trials for inclusion in this review. All studies evaluated external radiotherapy for control of metastatic bone pain. Twenty were excluded from the analysis. Eleven trials that involved 3435 patients were included. Of 3435 patients, 52 patients in two studies (<LINK REF="STD-Gaze-1997" TYPE="STUDY">Gaze 1997</LINK>; <LINK REF="STD-Ozsaran-2001a" TYPE="STUDY">Ozsaran 2001a</LINK>) were randomised more than once for different painful bone metastasis sites. Altogether, 3487 painful sites were randomised. Nine studies were two-arm studies i.e. single fraction versus multifraction. Two studies (<LINK REF="STD-Foro-1998a" TYPE="STUDY">Foro 1998a</LINK>; <LINK REF="STD-Ozsaran-2001a" TYPE="STUDY">Ozsaran 2001a</LINK>) randomised painful sites into 3 arms: single fraction versus two different multifraction schemes. Radomised painful sites in the single fraction arm of these two three-arm studies were counted twice in the analyses. Therefore, 3548 painful sites were included in the analyses.</P>
<P>The commonest primaries were prostate cancer (23.5%), breast cancer (39.3%) and lung cancer (19.9%). The most frequent treatment sites were spine (34%) and pelvis (32%). The radiation dose of the single fraction arm ranged from 8 Gy to 10 Gy. The schedules of the multifraction arm ranged from 5 Gy times 3 fractions (5 Gy x 3) to 3 Gy times 10 fractions (3 Gy x 10). The commonest schedules used were 4 Gy x 5 and 3 Gy x 10. A significant number of patients failed to complete the pain evaluation with dropout rates ranging from 0% to 69%.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-28 13:18:02 -0500" MODIFIED_BY="[Empty name]">
<P>Each study was evaluated for quality using the scale proposed by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). These scores were not used as a weighting factor for the analyses. As blinding is usually not feasible for radiotherapy treatment, the scoring questions for blinding were omitted in the quality evaluation. Thus, the maximum score is 3 instead of 5. The scoring questions are listed as below:<BR/>Question 1 (Q1): Is the study randomised? - 1 point for yes<BR/>Question 2 (Q2): Is the randomisation procedure reported or appropriate? - 1 point for yes<BR/>Question 3 (Q3): Are the reasons for withdrawals and dropouts described? - 1 point for yes</P>
<P>All the included studies were randomised. Only 1 out of 11 studies reported the randomisation procedure. Three studies described the reasons for withdrawals and dropouts. The quality scores of included studies are summarised in the table of characteristics of included study.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-28 13:24:22 -0500" MODIFIED_BY="[Empty name]">
<P>The pain response criteria employed by the included studies were quite heterogeneous. In this review, the criteria for overall and complete pain response of the original studies was used. If there was more than one time point for pain assessment, the time point at four weeks after treatment or closest to four weeks after treatment was used in the analyses. Despite this, the criteria for pain assessment may differ between studies. There was also significant amount of missing data due to dropouts in pain evaluation. To minimise bias arising from missing data, the primary analyses of this review were performed according to intention-to-treat principle (<LINK REF="REF-Lewis-1993" TYPE="REFERENCE">Lewis 1993</LINK>); i.e. all patients randomised into the original study were included, regardless of the compliance of the treatment or follow-up schedule. This is in contrast to most of the original studies, which excluded those patients who could not complete the subsequent pain evaluation. Repeated analyses excluding dropout patients were performed to test the robustness of the results.</P>
<P>Overall pain response (Forrest plot: intention-to-treat [ITT] - overall response)</P>
<P>All the studies reported overall pain response as one of the outcomes. Altogether, the analyses included 11 trials and 3548 painful sites. The overall pain response rates were similar for single fraction radiotherapy (1059/1779 = 60%) and multifraction radiotherapy (1038/1769 = 59%). The individual odds ratios ranged from 0.50 to 1.27 with a pooled odds ratio for all of the trials of 1.03 with a 95% confidence interval of 0.89 to 1.19. The test for heterogeneity was not statistically significant with P value of 0.7, which indicates that the pooling of the data was valid. The overall odds ratio suggests that there is no difference between single and multiple fraction radiotherapy in terms of overall pain response.</P>
<P>Complete pain response(Forrest plot: ITT - overall response)</P>
<P>Seven studies (<LINK REF="STD-BPTWP-1999" TYPE="STUDY">BPTWP 1999</LINK>; <LINK REF="STD-Gaze-1997" TYPE="STUDY">Gaze 1997</LINK>; <LINK REF="STD-Kagei-1990" TYPE="STUDY">Kagei 1990</LINK>; <LINK REF="STD-Koswig-1999" TYPE="STUDY">Koswig 1999</LINK>; <LINK REF="STD-Nielsen-1998" TYPE="STUDY">Nielsen 1998</LINK>; <LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>; <LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>) reported this outcome representing a total of 2876 patients. The complete pain response rates were 34% (497/1441) and 32% (463/1435) for single fraction radiotherapy and multifraction radiotherapy, respectively. The individual odds ratios varied from 0.82 to 3.00. The test for heterogeneity was not statistically significant (P = 0.81) allowing the results to be pooled. The overall odds ratio was 1.11 (95% CI 0.94 to 1.30) which suggests that there was no difference for complete pain response between the single and multiple fraction schedules.</P>
<P>Retreatment rate (Forrest plot: ITT - retreatment rate)</P>
<P>Five studies (<LINK REF="STD-BPTWP-1999" TYPE="STUDY">BPTWP 1999</LINK>; <LINK REF="STD-Cole-1989" TYPE="STUDY">Cole 1989</LINK>; <LINK REF="STD-Nielsen-1998" TYPE="STUDY">Nielsen 1998</LINK>; <LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>; <LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>) had reported re-treatment data and 2476 patients were included in the analysis. There were more retreatments after single fraction radiotherapy (267/1240 = 21.5%) compared to multifraction radiotherapy (91/1236 = 7.4%). The likelihood of re-treatment was 3.44-fold higher (95% CI 2.67 to 4.43) in single fraction radiotherapy arm patients. Test for heterogeneity was insignificant with P value of 0.18.</P>
<P>Pathological fracture (Forrest plot: ITT - fracture rate)</P>
<P>Five studies (<LINK REF="STD-BPTWP-1999" TYPE="STUDY">BPTWP 1999</LINK>; <LINK REF="STD-Cole-1989" TYPE="STUDY">Cole 1989</LINK>; <LINK REF="STD-Nielsen-1998" TYPE="STUDY">Nielsen 1998</LINK>; <LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>; <LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>) reported data for pathological fracture and included a total of 2476 patients. There were more pathological fractures in single fraction radiotherapy arm patients (37/1240 = 3%) than multifraction radiotherapy arm patients (20/1236 = 1.6%). The p-value ( 0.03) was marginally significant. The individual odds ratios varied considerably from 0.35 to 3.50, although the test for heterogeneity was not significant (P = 0.31). The overall odds ratio was 1.82 (95% CI 1.06 - 3.11) indicating that the risk of pathological fracture was 1.82 times higher in single fraction radiotherapy arm patients compared to the multiple fraction arm.</P>
<P>Spinal cord compression (Forrest plot: ITT - spinal 1 and spinal 2)</P>
<P>Only three studies (<LINK REF="STD-BPTWP-1999" TYPE="STUDY">BPTWP 1999</LINK>; <LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>; <LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>) reported the spinal cord compression rates. Two thousand, two hundred and six patients were randomised in these three studies. The spinal cord compression rates for all randomised patients were not different: 1.9% (21/1102) for single fraction patients and 1.4% (15/1104) for multifraction patients (P = 0.3) (Fig spinal 1).</P>
<P>Of these 2206 patients, only 739 patients had spinal metastases. Reanalysis using the data of these 739 patients showed a similar trend in that the rates were equivalent (single fraction vs multifraction: 5.6% vs 4%, P = 0.3). Tests for heterogeneity in the analysis were not significant (fig spinal 2). These three studies did not stratify the patients by site of involvement, therefore, the subset analysis was not strictly using data from a randomised study setting.</P>
<P>Repeated analyses of the above end points excluding dropout patients only did not alter the conclusions (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).<BR/>
<BR/>Side effects</P>
<P>Ten studies (<LINK REF="STD-BPTWP-1999" TYPE="STUDY">BPTWP 1999</LINK>; <LINK REF="STD-Cole-1989" TYPE="STUDY">Cole 1989</LINK>; <LINK REF="STD-Foro-1998a" TYPE="STUDY">Foro 1998a</LINK>; <LINK REF="STD-Gaze-1997" TYPE="STUDY">Gaze 1997</LINK>; <LINK REF="STD-Kagei-1990" TYPE="STUDY">Kagei 1990</LINK>; <LINK REF="STD-Nielsen-1998" TYPE="STUDY">Nielsen 1998</LINK>; <LINK REF="STD-Ozsaran-2001a" TYPE="STUDY">Ozsaran 2001a</LINK>; <LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>; <LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>) reported side effects of the treatment. The commonest side effects reported were nausea and vomiting and were similar in severity for both treatment arms. Only Foro et al reported that there were more transient increases in pain after single dose treatment, however, quantitative data were not available. The data were summarised in the table of characteristics of the included studies.<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-28 13:26:42 -0500" MODIFIED_BY="[Empty name]">
<P>This review confirms that radiotherapy is very effective in relieving metastatic bone pain. Up to 60% of patients will have some pain relief and about one third of them will have complete pain relief. Although the total patient number included in these randomised studies are large, there are still many unanswered questions. The most important problem is that there is no standard criterion in assessing the pain control. The pain assessment tool, the schedule of pain assessment and the definition of pain relief varied within the included studies. As reported in some of the studies (<LINK REF="STD-Kagei-1990" TYPE="STUDY">Kagei 1990</LINK>; <LINK REF="STD-Ozsaran-2001a" TYPE="STUDY">Ozsaran 2001a</LINK>; <LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>), the efficacy of pain relief would be different if the time point taken to assess the pain relief varied. Although there was variation in the pain response rates at different time points of assessment, the efficacy of single dose radiotherapy was the same as that of multifraction radiotherapy regardless of which time point was actually used (<LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>; <LINK REF="STD-Kagei-1990" TYPE="STUDY">Kagei 1990</LINK>). The only exception was the Ozsaran study which showed that assessment of pain relief on day 10 after radiotherapy favoured multifraction radiotherapy. The difference became insignificant on the first- and third-month reassessments. Future studies should follow more consistent pain assessment criteria to facilitate comparison and analysis and recently, guidelines for pain assessment were recommended by an international group which may be helpful for investigators in designing future studies (<LINK REF="REF-IBMC-2001" TYPE="REFERENCE">IBMC 2001</LINK>; <LINK REF="REF-Hoskin-2001a" TYPE="REFERENCE">Hoskin 2001a</LINK>).</P>
<P>There was a significant amount of missing data in the pain assessment with dropout rates ranging from 0% to 69%. Common reasons for missing data were patient death and significant ill health preventing the patients from filling in the assessment form. The dropout patients were usually excluded from the pain response analyses. Therefore, most of the analyses were not using the intention-to-treat principle. This may be reasonable if we assume symptomatic relief is irrelevant after patient's death. Nevertheless, whether symptom relief can be achieved or not when a patient's death is imminent, remains uncertain. This is a potential bias when a large proportion of patients are excluded from analysis.</P>
<P>The retreatment rate is 3.4-fold higher in patients treated by single fraction radiotherapy which will counteract the advantages of single fraction radiotherapy. The reasons for the higher re-treatment rate are multiple. One possibility is that the pain response is less durable resulting in re-treatment in subsequent clinical course. However, in studies (<LINK REF="STD-Gaze-1997" TYPE="STUDY">Gaze 1997</LINK>; <LINK REF="STD-Nielsen-1998" TYPE="STUDY">Nielsen 1998</LINK>; <LINK REF="STD-Price-1986" TYPE="STUDY">Price 1986</LINK>; <LINK REF="STD-BPTWP-1999" TYPE="STUDY">BPTWP 1999</LINK>; <LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>) that analysed the time to pain progression or duration of response, there was no evidence that the time to progression was shorter in single dose radiotherapy arm. Therefore, it is unlikely to be the major contributing cause for the higher re-treatment rate. The other possible reason for the higher re-treatment rate in single dose treatment patients is that many oncologists are not willing to give re-treatment after multifraction radiotherapy unless the patient has significant pain. In the Dutch Bone Metastasis Study (<LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>), the pain score before re-treatment was higher in the multifraction radiotherapy group. The possible explanation may be the concern about the potential radiotherapy toxicities after an initial higher dose treatment. The scenario will be different for single dose treatment when the radiotherapy dose is lower. Thus, it is difficult to ascertain that multifraction radiotherapy, in this respect, is superior.</P>
<P>The pathological fracture rate is higher in the single dose radiotherapy arm. The absolute difference of the rate is only 1.3% (3% vs 1.7%). The number needed to treat is about 77, i.e. about 1 more patient will experience pathological fracture when 77 patients are treated by single dose radiotherapy. Although the difference is small, this is a significant complication that should not be overlooked lightly. Theoretically, the difference may be even higher for those who have a more lytic lesion and for those who have a longer survival.</P>
<P>It should be noted that there is a trend of increasing spinal cord compression rates in all three studies analysed for this outcome. However, the number of events were too small to allow sufficient statistical power to test the difference.</P>
<P>There was minimal data to address quality of life issues which should be included in the reporting in future studies. In addition, scant information was available relating to health economics. In the Dutch Bone Metastasis Study (<LINK REF="STD-Steenland-1999" TYPE="STUDY">Steenland 1999</LINK>), the difference in the cost for the two schedules was about 570 Euros in favour of single dose treatment. Nevertheless, the analysis did not include treatment costs for the higher number of pathological fractures.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>In conclusion, radiotherapy is effective in relieving metastatic bone pain. There is no difference in the efficacy between single fraction radiotherapy and multifraction radiotherapy. However, the re-treatment rate and pathological fracture rate are higher after single dose radiotherapy. Multifraction radiotherapy remains one of the alternatives in treating metastatic bone pain. This is especially so for patients with lytic lesions and long life expectancy. More data are needed to find out the optimal treatment strategy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Although a significant proportion of patients had some pain relief after radiotherapy, complete pain relief was still not achieved in about two-thirds of patients. The incorporation of different modalities like radio-isotopes or medications e.g. bisphosphonates may further improve the pain relief efficacy. Studies testing the optimal use of various modalities are warranted. More refinement of patient selection such as subsets of different life expectancy and various types of pain, will be helpful to address these questions. Future studies should use standardised criteria for pain assessment so that results can be compared. A more robust statistical approach should be applied to minimize the impact of missing data. Quality of life and health economics end points should be incorporated into the study protocol.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>This project formed the basis for an M. Sc. in Palliative Medicine, UK. The authors are extremely grateful for the time and effort of Mrs Lynda Churchill in translating Foro et al 1998 [Spanish] and Ms Noguchi Kumiko, Ms Betty MY Choi and Dr VC Sin in translating Kagei et al 1990 [Japanese].</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Dr Wai Man Sze: Primary contact, literature search and screen, data extraction, analysis, draft manuscript, quality assessment.</P>
<P>Dr Mike Shelley: secondary contact, literature search, translations, review analysis, draft manuscript, quality assessment.</P>
<P>Dr Ines Held: Translations, review manuscript</P>
<P>Professor Malcolm Mason: Review manuscript, review analysis, quality assessment</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2011-04-05 09:23:07 -0500" MODIFIED_BY="James Tacklind">
<P>The primary author has indicated he will not be updating this review.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-28 13:04:49 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-05-28 13:00:19 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-05-28 12:58:22 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-BPTWP-1999" NAME="BPTWP 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bone Pain Trial Working Party</AU>
<TI>8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>2</NO>
<PG>111-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cole-1989" NAME="Cole 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cole DJ</AU>
<TI>A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases</TI>
<SO>Clinical Oncology</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>2</NO>
<PG>59-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foro-1998a" MODIFIED="2008-05-28 12:58:08 -0500" MODIFIED_BY="[Empty name]" NAME="Foro 1998a" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Foro, P., M. Algara, et al. (1998). &amp;quot;Randomized prospective trial comparing three schedules of palliative radiotherapy. Preliminary results. [Spanish].&amp;quot; Oncologia 21(11): 55-60.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Foro P, Algara M, Reig A, Lacruz M, Valls A</AU>
<TI>Randomized prospective trial comparing three schedules of palliative radiotherapy. Preliminary results. [Spanish]</TI>
<SO>Oncologia</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>11</NO>
<PG>55-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foro-1998b" MODIFIED="2008-05-28 12:57:52 -0500" MODIFIED_BY="[Empty name]" NAME="Foro 1998b" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Foro P, Algara M, Reig A, Lacruz, A Valls</AU>
<TI>Randomized prospective trial comparing three schedules of palliative radiotherapy. Preliminary results. [Spanish]</TI>
<SO>Oncologia</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>11</NO>
<PG>55-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaze-1997" NAME="Gaze 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A, Howard GC, Rodger A</AU>
<TI>Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1997</YR>
<VL>45</VL>
<NO>2</NO>
<PG>109-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kagei-1990" NAME="Kagei 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kagei K, Suzuki K, Shirato H, Nambu T, Yoshikawa H, Irie G</AU>
<TI>[A randomized trial of single and multifraction radiation therapy for bone metastasis: a preliminary report]</TI>
<SO>Gan No Rinsho</SO>
<YR>1990</YR>
<VL>36</VL>
<NO>15</NO>
<PG>2553-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koswig-1999" NAME="Koswig 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Koswig, S. and V. Budach (1999). &amp;quot;Recalcification and pain relief following radiotherapy for bone metastases. A randomized trial of 2 different fractionation schedules (10 x 3 Gy vs 1 x 8 Gy). [German].&amp;quot; Strahlentherapie und Onkologie 175(10): 500-508.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koswig, S, Budach V</AU>
<TI>Recalcification and pain relief following radiotherapy for bone metastases. A randomized trial of 2 different fractionation schedules (10 x 3 Gy vs 1 x 8 Gy). [German]</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1999</YR>
<VL>175</VL>
<NO>10</NO>
<PG>500-508</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen-1998" NAME="Nielsen 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR</AU>
<TI>Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>3</NO>
<PG>233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozsaran-2001a" MODIFIED="2008-05-28 12:58:22 -0500" MODIFIED_BY="[Empty name]" NAME="Ozsaran 2001a" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Ozsaran, Z., D. Yalman, et al. (2001). &amp;quot;Palliative radiotherapy in bone metastases: Results of a randomized trial comparing three fractionation schedules.&amp;quot; Journal of B.U.On. 6(1): 43-48.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ozsaran Z, Yalman D, Anacak Y, Esassolak M, Haydaroglu A</AU>
<TI>Palliative radiotherapy in bone metastases: Results of a randomized trial comparing three fractionation schedules</TI>
<SO>Journal BUON</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>43-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozsaran-2001b" MODIFIED="2008-05-28 12:56:46 -0500" MODIFIED_BY="[Empty name]" NAME="Ozsaran 2001b" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ozsaran Z, Yalman D, Anacak Y, Esassolak M, Haydaroglu A</AU>
<TI>Palliative radiotherapy in bone metastases: Results of a randomized trial comparing three fractionation schedules</TI>
<SO>Journal of BUON</SO>
<YR>2001</YR>
<VL>6</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1986" NAME="Price 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR</AU>
<TI>Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>4</NO>
<PG>247-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steenland-1999" NAME="Steenland 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, de Haes H, Martijn H, Oei B, Vonk E, van der Steen-Banasik E, Wiggenraad RG, Hoogenhout J, Warlam-Rodenhuis C, van Tienhoven G, Wanders R, Pomp J, van Reijn M, van Mierlo I, Rutten E, Leer J, van Mierlo T</AU>
<TI>The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>2</NO>
<PG>101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warde-2001" NAME="Warde 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Warde PR, Kirkbride P, Panzarella T.</AU>
<TI>Single fraction vs fractionated radiation therapy in the palliation of skeletal metastases - a randomised phase III trial." International Journal of Radiation Oncology, Biology, Physics 48(3 Suppl</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>abstract 1538</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-05-28 13:00:19 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arcangeli-1998" MODIFIED="2008-05-28 12:59:58 -0500" MODIFIED_BY="[Empty name]" NAME="Arcangeli 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arcangeli G, Giovinazzo G, Saracino B, D'Angelo L, Giannarelli D, Micheli A.</AU>
<TI>Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>5</NO>
<PG>1119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blitzer--1985" NAME="Blitzer  1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blitzer PH</AU>
<TI>Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis</TI>
<SO>Cancer</SO>
<YR>1985</YR>
<VL>55</VL>
<NO>7</NO>
<PG>1468-1472</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borojevic-1999" NAME="Borojevic 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Borojevic N, Golubicic I, Rado&#353;evic-Jelic L.</AU>
<TI>The responsivness of bone metastases in breast cancer patients to radiotherapy: Prospective study comparing six different fractionation schedules</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>Suppl. 4</NO>
<PG>abstract 1326</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bremer-1999" NAME="Bremer 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bremer M, Rades D, Blach M, Krenkel B, Karstens JH</AU>
<TI>Effectiveness of hypofractionated radiotherapy in painful bone metastases. Two prospective studies with 1 x 4 Gy and 4 x 4 Gy</TI>
<SO>Strahlenther Onkol</SO>
<YR>1999</YR>
<VL>175</VL>
<NO>8</NO>
<PG>382-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foro-1998" NAME="Foro 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Foro P, Algara M, Reig A, et al</AU>
<TI>Randomized clinical trial comparing two schedules of treatment for painful bone metastases. 6 vs 8 Gy single doses</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>Suppl. 1</NO>
<PG>Abstract 834</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirokawa-1988" NAME="Hirokawa 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirokawa Y, Wadasaki K, Kashiwado K, Kagemoto M, Katsuta S, Honke Y, Koyama T, Makidono Y, Katayama H, Kiso T</AU>
<TI>[A multi-institutional prospective randomized study of radiation therapy of bone metastases]</TI>
<SO>Nippon Igaku Hoshasen Gakkai Zasshi</SO>
<YR>1988</YR>
<VL>48</VL>
<NO>11</NO>
<PG>1425-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoskin-1992" NAME="Hoskin 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, Yarnold JR</AU>
<TI>A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>2</NO>
<PG>74-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeremic-1998" NAME="Jeremic 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, Aleksandrovic J, Igrutinovic I</AU>
<TI>A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain</TI>
<SO>International Journal Radiation Oncology Biology Physics</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>1</NO>
<PG>161-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madsen-1983" NAME="Madsen 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madsen EL</AU>
<TI>Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy X 6 versus 10 Gy X 2</TI>
<SO>International Journal Radiation Oncology Biology Physics</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>12</NO>
<PG>1775-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maranzano-2000" NAME="Maranzano 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Maranzano E, Frattegiani I, Piro F, et al</AU>
<TI>Randomized trial of short-course versus split-course radiotherapy (RT) in metastatic spinal cord compression (MSCC). An interim analysis. Radiother Oncol 2000;56(Suppl</TI>
<SO>Radiotherapy Oncology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>Suppl. 1</NO>
<PG>abstract 62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niewald-1996" MODIFIED="2008-05-28 13:00:19 -0500" MODIFIED_BY="[Empty name]" NAME="Niewald 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niewald M, Tkocz HJ, Abel U et al</AU>
<TI>Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases</TI>
<SO>International Journal Radiation Oncology Biology Physics</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>5</NO>
<PG>1085-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okawa-1988" NAME="Okawa 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okawa T, Kita M, Goto M, Nishijima H, Miyaji N</AU>
<TI>Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1988</YR>
<VL>13</VL>
<NO>2</NO>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poulter-1992" NAME="Poulter 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poulter CA, Cosmatos D, Rubin P, et al</AU>
<TI>A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>1</NO>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmusson-1995" NAME="Rasmusson 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmusson B, Vejborg I, Jensen AB, Andersson M, Banning AM, Hoffmann T, Pfeiffer P, Nielsen HK, Sjogren P</AU>
<TI>Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>3</NO>
<PG>179-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salazar-1996" NAME="Salazar 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salazar OM, DaMotta NW, Bridgman SM, Cardiges NM, Slawson RG</AU>
<TI>Fractionated half-body irradiation for pain palliation in widely metastatic cancers: comparison with single dose</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>1</NO>
<PG>49-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salazar-2001" NAME="Salazar 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salazar OM, Sandhu T, da Motta NW, et al</AU>
<TI>Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>3</NO>
<PG>765-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tombolini-1994" NAME="Tombolini 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tombolini V, Zurlo A, Montagna A, et al</AU>
<TI>Radiation therapy of spinal metastases: results with different fractionations</TI>
<SO>Tumori</SO>
<YR>1994</YR>
<VL>80</VL>
<NO>5</NO>
<PG>353-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-1982" NAME="Tong 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tong D, Gillick L, Hendrickson FR</AU>
<TI>The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group</TI>
<SO>Cancer</SO>
<YR>1982</YR>
<VL>50</VL>
<NO>5</NO>
<PG>893-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zelefsky-1989" NAME="Zelefsky 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zelefsky MJ, Scher HI, Forman JD, Linares LA, Curley T, Fuks Z</AU>
<TI>Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>6</NO>
<PG>1281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Roos-2000" NAME="Roos 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roos DE, O'Brien PC, Smith JG, Spry NA, Hoskin PJ, Burmeister BH, Turner SL, Bernshaw DM</AU>
<TI>A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05)</TI>
<SO>International Journal Radiation Oncology Biology Physics</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>4</NO>
<PG>975-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-28 13:04:49 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-28 13:04:49 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barak-1987" NAME="Barak 1987" TYPE="JOURNAL_ARTICLE">
<AU>Barak F, Werner A, Walach N, Horn Y</AU>
<TI>The palliative efficacy of a single high dose of radiation in treatment of symptomatic osseous metastases</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>8</NO>
<PG>1233-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bates-1992a" MODIFIED="2008-05-28 13:01:41 -0500" MODIFIED_BY="[Empty name]" NAME="Bates 1992a" TYPE="JOURNAL_ARTICLE">
<AU>Bates T</AU>
<TI>A review of local radiotherapy in the treatment of bone metastases and cord compression</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>1</NO>
<PG>217-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bates-1992b" MODIFIED="2008-05-28 13:01:34 -0500" MODIFIED_BY="[Empty name]" NAME="Bates 1992b" NOTES="&lt;p&gt;4. Bates T, Yarnold JR, Blitzer P, Nelson OS, Rubin P, Maher J. Bone metastasis consensus statement. International Journal of Radiation Oncology, Biology, Physics 1992;23(1):215-6.&lt;/p&gt;" NOTES_MODIFIED="2008-05-28 13:01:34 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Bates T, Yarnold JR, Blitzer P, Nelson OS, Rubin P, Maher J.</AU>
<TI>Bone metastasis consensus statement</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>1</NO>
<PG>215-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ben_x002d_Josef-1998" NAME="Ben-Josef 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ben-Josef E, Shamsa F, Williams AO, Porter AT</AU>
<TI>Radiotherapeutic management of osseous metastases: a survey of current patterns of care</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1998</YR>
<VL>40</VL>
<NO>4</NO>
<PG>915-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ben_x002d_Josef-1999" NAME="Ben-Josef 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ben-Josef E, Shamsa F, Youssef E, Porter AT</AU>
<TI>External beam radiotherapy for painful osseous metastases: Pooled data dose response analysis</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>3</NO>
<PG>715-719</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2001" NAME="Brown 2001" TYPE="BOOK">
<AU>Brown HK, Healey JH</AU>
<TI>Metastatic cancer to the bone. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer - Principles &amp; Practice of Oncology. 6 ed</TI>
<SO>Cancer - Principles &amp; Practice of Oncology</SO>
<YR>2001</YR>
<PG>2713 - 2729</PG>
<EN>6</EN>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunting-2001" NAME="Bunting 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bunting RW, Shea B</AU>
<TI>Bone metastasis and rehabilitation</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>4 Suppl</NO>
<PG>1020-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chander-1999" NAME="Chander 1999" TYPE="JOURNAL_ARTICLE">
<AU>Chander SS, Sarin R</AU>
<TI>Single fraction radiotherapy for bone metastases: are all questions answered?</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>2</NO>
<PG>191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chow-2000" NAME="Chow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chow E, Danjoux C, Wong R, et al</AU>
<TI>Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists</TI>
<SO>Radiotherapy Oncology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>3</NO>
<PG>305-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-2001" NAME="Cook 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cook RJ, Major P</AU>
<TI>Methodology for treatment evaluation in patients with cancer metastatic to bone</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2001</YR>
<VL>93</VL>
<NO>7</NO>
<PG>534-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crellin-1989" NAME="Crellin 1989" TYPE="JOURNAL_ARTICLE">
<AU>Crellin AM, Marks A, Maher EJ</AU>
<TI>Why don't British radiotherapists give single fractions of radiotherapy for bone metastases?</TI>
<SO>Clinical Oncology</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>2</NO>
<PG>63-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawson-1999" NAME="Dawson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dawson R, Currow D, Stevens G, Morgan G, Barton MB</AU>
<TI>Radiotherapy for bone metastases: a critical appraisal of outcome measures</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>3</NO>
<PG>208-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-1999" NAME="Deeks 1999" TYPE="BOOK">
<AU>Deeks J</AU>
<TI>Statistical Methods Programmed in MetaView Version 4</TI>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duncan-1993" NAME="Duncan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Duncan G, Duncan W, Maher EJ</AU>
<TI>Patterns of palliative radiotherapy in Canada</TI>
<SO>Clinical Oncology</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>2</NO>
<PG>92-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higinbotham-1965" NAME="Higinbotham 1965" TYPE="JOURNAL_ARTICLE">
<AU>Higinbotham NL, Marcove RC</AU>
<TI>The management of pathological fractures</TI>
<SO>Journal Trauma</SO>
<YR>1965</YR>
<VL>5</VL>
<NO>6</NO>
<PG>792-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoegler-1997" NAME="Hoegler 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hoegler D</AU>
<TI>Radiotherapy for palliation of symptoms in incurable cancer</TI>
<SO>Current Problems in Cancer</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>3</NO>
<PG>129-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoskin--2001b" MODIFIED="2008-05-28 13:02:16 -0500" MODIFIED_BY="[Empty name]" NAME="Hoskin  2001b" TYPE="JOURNAL_ARTICLE">
<AU>Hoskin PJ, Yarnold JR, Roos DR, Bentzen S</AU>
<TI>Second Workshop on Palliative R, Symptom C. Radiotherapy for bone metastases</TI>
<SO>Clinical Oncology</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>88-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoskin-2001a" MODIFIED="2008-05-28 13:02:05 -0500" MODIFIED_BY="[Empty name]" NAME="Hoskin 2001a" TYPE="CONFERENCE_PROC">
<AU>Hoskin P, Chow E, Wu J, Coia L</AU>
<TI>ESTRO/ASTRO consensus statement on the measurement of metastatic bone pain in radiotherapy trials</TI>
<SO>European Journal of Cancer</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>Supplement 6</NO>
<PG>Abstract 962</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IBMC-2001" NAME="IBMC 2001" TYPE="JOURNAL_ARTICLE">
<AU>International bone metastases consensus</AU>
<TI>International bone metastases consensus on endpoint measurements for future clinical trials: proceedings of the first survey and meeting (work in progress) International Bone Metastases Consensus Working Party</TI>
<SO>Clinical Oncology</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>82-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janjan-1998" NAME="Janjan 1998" TYPE="JOURNAL_ARTICLE">
<AU>Janjan NA, Payne R, Gillis T, et al</AU>
<TI>Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>3</NO>
<PG>171-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawton-1991" NAME="Lawton 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lawton PA, Maher EJ</AU>
<TI>Treatment strategies for advanced and metastatic cancer in Europe</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1991</YR>
<VL>22</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-1993" NAME="Lewis 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lewis JA, Machin D</AU>
<TI>Intention to treat--who should use ITT?</TI>
<SO>British Journal Cancer</SO>
<YR>1993</YR>
<VL>68</VL>
<NO>4</NO>
<PG>647-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lievens-2000" NAME="Lievens 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lievens Y, Kesteloot K, Rijnders A, Kutcher G, Van den Bogaert W</AU>
<TI>Differences in palliative radiotherapy for bone metastases within Western European countries</TI>
<SO>Radiotherapy Oncology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>3</NO>
<PG>297-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lievens-Y-2000" NAME="Lievens Y 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lievens Y, Van den Bogaert W, Rijnders A, Kutcher G, Kesteloot K</AU>
<TI>Palliative radiotherapy practice within Western European countries: impact of the radiotherapy financing system? [see comments]</TI>
<SO>Radiotherapy Oncology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>3</NO>
<PG>289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macklis-1998" NAME="Macklis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Macklis RM, Cornelli H, Lasher J</AU>
<TI>Brief courses of palliative radiotherapy for metastatic bone pain: a pilot cost-minimization comparison with narcotic analgesics</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>6</NO>
<PG>617-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maher-1992" NAME="Maher 1992" TYPE="JOURNAL_ARTICLE">
<AU>Maher EJ, Coia L, Duncan G, Lawton PA</AU>
<TI>Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>1</NO>
<PG>239-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-2001" NAME="McQuay 2001" TYPE="COCHRANE_REVIEW">
<AU>McQuay HJ, Collins SL, Carroll D, Moore RA</AU>
<TI>Radiotherapy for the palliation of painful bone metastases (Cochrane Review)</TI>
<SO>The Cochrane Library (Oxford: Update Software)</SO>
<YR>2001</YR>
<NO>3</NO>
<PG>CD001793</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porter-1994" NAME="Porter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Porter AT, Fontanesi J</AU>
<TI>Palliative irradiation for bone metastasis -a new paradigm</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1994</YR>
<VL>29</VL>
<NO>5</NO>
<PG>1199-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priestman-1989" NAME="Priestman 1989" TYPE="JOURNAL_ARTICLE">
<AU>Priestman TJ, Bullimore JA, Godden TP, Deutsch GP</AU>
<TI>The Royal College of Radiologists' Fractionation Survey</TI>
<SO>Clinical Oncology</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>1</NO>
<PG>39-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ratanatharathorn--1999" MODIFIED="2008-05-28 13:04:49 -0500" MODIFIED_BY="[Empty name]" NAME="Ratanatharathorn  1999" TYPE="JOURNAL_ARTICLE">
<AU>Ratanatharathorn V, Powers WE, Moss WT, Perez CA</AU>
<TI>Bone metastasis: review and critical analysis of random allocation trials of local field treatment</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1999</YR>
<VL>44</VL>
<NO>1</NO>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roos--2000a" MODIFIED="2008-05-28 13:03:12 -0500" MODIFIED_BY="[Empty name]" NAME="Roos  2000a" TYPE="JOURNAL_ARTICLE">
<AU>Roos DE</AU>
<TI>Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: an Australian and New Zealand practice survey and literature review</TI>
<SO>Radiotherapy Oncology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>3</NO>
<PG>315-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roos-2000b" MODIFIED="2008-05-28 13:03:17 -0500" MODIFIED_BY="[Empty name]" NAME="Roos 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Roos DE, Davis SR, O'Brien PC, et al</AU>
<TI>Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05)</TI>
<SO>Australasian Radiology</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>3</NO>
<PG>303-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-1998" NAME="Rose 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rose CM, Kagan AR</AU>
<TI>The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1998</YR>
<VL>40</VL>
<NO>5</NO>
<PG>1117-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevens-1995" NAME="Stevens 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stevens G, Firth I</AU>
<TI>Patterns of fractionation for palliation of bone metastases</TI>
<SO>Australasian Radiology</SO>
<YR>1995</YR>
<VL>39</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-BPTWP-1999">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/1)<BR/>Pain assessment <BR/>criteria: 4 -point category for pain<BR/>Response - improvement by at least 1 category within 1 year<BR/>Complete response - no pain<BR/>Pain assessment schedule: 2 weeks, 1,2,3,4,5,6,8,10 and 12 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastasis<BR/>Exclusion: pathological #<BR/>Randomised sites: 383 vs 378<BR/>Primary tumours:prostate (34%), breast (36%), lung (12%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>4 Gy x 5 or 3Gy x 10 <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Complete response<BR/>Re-treatment<BR/>Fracture<BR/>Spinal cord compression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:80 / 761 (10.5%)<BR/>Time point taken for pain response analysis in this review: Within 1 year<BR/>Side effects:<BR/>Nausea 56% vs 65%<BR/>Vomiting 30% vs 32%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cole-1989">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: Five point categorical pain score<BR/>Response - Best score within 6 months with at least improvement by one category.<BR/>Pain assessment schedule: Daily chart by patients for 28 days from start of treatment. Monthly assessment by doctor</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastasis.<BR/>Neurologic compression, established or impending <BR/>pathological # excluded<BR/>Randomised sites: 16 vs 13<BR/>Primary tumours:prostate (14%), breast (48%), lung (21%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>4 Gy x 6<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Re-treatment<BR/>Fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment: Not reported<BR/>Side effects:<BR/>Nausea and vomiting 77% vs 33%<BR/>Diarrhoea 30% vs 22%<BR/>Skin reaction 30% vs 22%<BR/>Time point taken for pain response analysis in this review: Same as the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Foro-1998a">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: Visual analogue scale (VAS)<BR/>Response - improvement by 2 or more points at any assessment<BR/>Pain assessment schedule: one month then 3 monthly for 1 year or till death</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastasis. Included at risk of pathological # or cord compression<BR/>Randomised sites: 25 vs 25 vs 25<BR/>Primary tumours:prostate (15%), breast (40%), lung (17%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>5 Gy x 3 <BR/>vs <BR/>3 Gy x 10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:13 / 75 (17.3%)<BR/>Time point taken for pain response analysis in this review: Same as the study<BR/>Side effects:<BR/>Transient increase in pain in single dose arm 15%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Foro-1998b">
<CHAR_METHODS>
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gaze-1997">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: 5 point categorical pain score and analgesic score<BR/>Response - improvement of pain score by 1 category at 1 week or 1 month assessment<BR/>Complete response - pain score = 0<BR/>Pain assessment schedule: 1 week, 1 month and then 2 monthly after treatment<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastasis.<BR/>Life expectancy &lt; 4 weeks, cord compression, established or threatened pathological # excluded<BR/>Randomised sites: 151 vs 144<BR/>Primary tumours:prostate (20%), breast (44%), lung (16%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>10 Gy x 1 <BR/>vs <BR/>4.5 Gy x 5<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Complete response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:55 / 295 (18.6%)<BR/>Time point taken for pain response analysis in this review: Same as the study<BR/>Side effects:<BR/>Grade 3/4 tiredness and latssitude 13% vs 16%<BR/>Grade 3/4 nausea and vomiting 12% vs 15%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kagei-1990">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: Four point categorical pain score<BR/>Response - improvement of pain score by at least 1 category at 8-week assessment<BR/>Complete response - pain score =0<BR/>Pain assessment schedule: 1,2,3,4 and 8 weeks after start of treatment<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful metastasis<BR/>Exclusion: fracture and spinal cord compression<BR/>Randomised sites: 14 vs 13<BR/>Primary tumours:prostate (7%), breast (15%), lung (19%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 or 10 or 12 or 15 Gy x 1 <BR/>vs <BR/>5 Gy x 4 or 5 Gy x 5 or 5 Gy x 6<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Complete response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:0/27 (0%)<BR/>Time point taken for pain response analysis in this review: Same as the study<BR/>Side effects:<BR/>Nausea and vomiting 14% vs 23%<BR/>Diarrhoea 21% vs 15%<BR/>Transient increase in pain 0% vs 8%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Koswig-1999">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: information N/A<BR/>Pain assessment schedule: Day after, 6 weeks, 3 and 6 months after RT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastasis<BR/>Randomised sites: 52 vs 55<BR/>Primary tumours:prostate (10%), breast (58%), lung (24%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>3 Gy x 10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Complete response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment: not reported<BR/>Time point taken for pain response analysis in this review: Same as the study<BR/>Side effects: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nielsen-1998">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/1/1)<BR/>Pain assessment criteria: Visual analogue scale and a 5 point categorical scale<BR/>Response - &gt; 50% reduction in VAS or improvement of at least one category at any time point<BR/>Complete response - complete absence of pain<BR/>Pain assessment schedule: 4, 8, 12, 20 weeks after beginning of RT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastases with life expectancy &gt; 6 weeks<BR/>Pathological # and cord compression excluded<BR/>Randomised sites: 122 vs 119<BR/>Primary tumours:prostate (33%), breast (39%), lung (12%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>4 Gy x 5<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Complete response<BR/>Re-treatment<BR/>Fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:32 / 239 (13.4%)<BR/>Time point taken for pain response analysis in this review: Visual analogue scale at 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ozsaran-2001a">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: 4 categorical scales for pain and analgesic requirement <BR/>Response - Considerable pain relief, minimal analgesic requirement (60-90% response)<BR/>Complete response - complete pain relief (100% response)<BR/>Pain assessment schedule: 10 days, 1 month and 3 months after RT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastasis<BR/>Randomised sites: 36 vs 38 vs 35<BR/>Primary tumours:prostate (5%), breast (44%), lung (26%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>4 Gy x 5 <BR/>vs <BR/>3 Gy x 10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:Information N/A<BR/>Time point taken for pain response analysis in this review: Pain response at 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ozsaran-2001b">
<CHAR_METHODS>
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Price-1986">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: 4 -point category for pain<BR/>Response - improvement by at least 1 category within 1 year<BR/>Complete response - no pain<BR/>Pain assessment schedule: 2 weeks, 1,2,3,4,5,6,8,10 and 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastases with life expectancy &gt; 6 weeks<BR/>Exclusion: pathological # of long bone<BR/>Randomised sites: 140 vs 148<BR/>Primary tumours:prostate (8%), breast (37%), lung (20%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>3 Gy x 10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Complete response<BR/>Re-treatment<BR/>Fracture<BR/>Spinal cord compression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:At 4 weeks, 179 / 288 (62%)<BR/>At 3 months, 199 / 288 (69%)<BR/>Time point taken for pain response analysis in this review: At 4 weeks<BR/>Side effects: no increase in acute toxicities</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Steenland-1999">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/1)<BR/>Pain assessment criteria: 11-point category <BR/>Response - decrease by at least 2 points within 1 year<BR/>Complete response - pain score 0,1 independent of analgesic use<BR/>Pain assessment schedule: Weekly for 3 months then 4 weekly up to 2 years<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastases with pain score &gt; 2<BR/>Exclusion: pathological # or spinal cord compression<BR/>Randomised sites: 579 vs 578<BR/>Primary tumours:prostate (23%), breast (39%), lung (25%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>4 Gy x 6<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response<BR/>Complete response<BR/>Re-treatment<BR/>Fracture<BR/>Spinal cord compression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:95 / 1157 (8%)<BR/>Time point taken for pain response analysis in this review: Within 1 year<BR/>Side effects:<BR/>Nausea, vomiting and skin reaction same</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Warde-2001">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Quality score (1/0/0)<BR/>Pain assessment criteria: Response - decrease in pain sore with reduced analgesics or pain score of zero without increase in analgesic at 3 months after treatment<BR/>Pain assessment schedule: Information N/A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Painful bone metastasis with life expectancy &gt; 4 months<BR/>Randomised sites: 200 vs 198<BR/>Primary tumours:prostate (23%), breast (40%), lung (26%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 <BR/>vs <BR/>4 Gy x 5<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data in pain assessment:137 / 398 (34%)<BR/>Time point taken for pain response analysis in this review: Same as the study<BR/>Side effects: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arcangeli-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study, mainly comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blitzer--1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borojevic-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bremer-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foro-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of single fraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hirokawa-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoskin-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of single fraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jeremic-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of single fraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Madsen-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maranzano-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ongoing randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niewald-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okawa-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poulter-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study addressing the role of single dose half body irradiation on top of multifraction local field radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rasmusson-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salazar-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study for pain caused by disseminated malignancy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salazar-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study comparing different schedules of multifraction half-body irradiation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tombolini-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tong-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Same randomised study data as Blitzer 1985. Study comparing different schedules of multifraction radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zelefsky-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Roos-2000">
<CHAR_STUDY_NAME>
<P>Trans-Tasman Radiation Oncology Group (TROG) 96.05</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients with bone metastasis causing neuropathic bone pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 Gy x 1 vs 4 Gy x 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response 59% (response of each arm not reported)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Feb 96</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-BPTWP-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cole-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Foro-1998a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Foro-1998b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gaze-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kagei-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Koswig-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nielsen-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ozsaran-2001a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ozsaran-2001b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Price-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Steenland-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Warde-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-28 12:41:18 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-05-28 12:41:18 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Re-analyses using evaluable patients only</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Single fraction</P>
</TH>
<TH>
<P>Multifraction</P>
</TH>
<TH>
<P>Odds ratio</P>
</TH>
<TH>
<P>P value</P>
</TH>
<TH>
<P>Heterogeneity</P>
</TH>
</TR>
<TR>
<TD>
<P>Overall pain response</P>
</TD>
<TD>
<P>70% (1059/1519)</P>
</TD>
<TD>
<P>71.7% (1038/1447)</P>
</TD>
<TD>
<P>0.90<BR/>(0.76-1.06)</P>
</TD>
<TD>
<P>0.19</P>
</TD>
<TD>
<P>0.45</P>
</TD>
</TR>
<TR>
<TD>
<P>Complete pain response</P>
</TD>
<TD>
<P>40% (497/1246)</P>
</TD>
<TD>
<P>39% (463/1186)</P>
</TD>
<TD>
<P>1.03<BR/>(0.87-1.22)<BR/>
</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>0.69</P>
</TD>
</TR>
<TR>
<TD>
<P>Re-treatment</P>
</TD>
<TD>
<P>22.6% (267/1184)</P>
</TD>
<TD>
<P>7.6% (91/1185)</P>
</TD>
<TD>
<P>3.49<BR/>(2.71- 4.5)<BR/>
</P>
</TD>
<TD>
<P>&lt;0.00001</P>
</TD>
<TD>
<P>0.22</P>
</TD>
</TR>
<TR>
<TD>
<P>Fracture</P>
</TD>
<TD>
<P>3% (37/1206)</P>
</TD>
<TD>
<P>1.7% (20/1188)</P>
</TD>
<TD>
<P>1.81<BR/>(1.05-3.11)<BR/>
</P>
</TD>
<TD>
<P>0.03</P>
</TD>
<TD>
<P>0.33</P>
</TD>
</TR>
<TR>
<TD>
<P>Cord compression (all patients)</P>
</TD>
<TD>
<P>1.9% (21/1070)</P>
</TD>
<TD>
<P>1.4% (15/1056)</P>
</TD>
<TD>
<P>1.39<BR/>(0.71-2.71)<BR/>
</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>0.93</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-005" NO="5">
<NAME>Intention-to-treat</NAME>
<DICH_OUTCOME CHI2="12.568466048646059" CI_END="1.1913796690214993" CI_START="0.8929746181516468" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0314416149342185" ESTIMABLE="YES" EVENTS_1="1059" EVENTS_2="1038" I2="4.522954881254557" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.0760501845599442" LOG_CI_START="-0.049160885292125575" LOG_EFFECT_SIZE="0.013444649633909298" METHOD="MH" NO="1" P_CHI2="0.40117017358332663" P_Q="1.0" P_Z="0.673823914012474" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1779" TOTAL_2="1769" WEIGHT="99.99999999999999" Z="0.4209057409756852">
<NAME>Overall response</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Multiple</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Single</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.568466048646059" CI_END="1.1913796690214993" CI_START="0.8929746181516468" DF="12" EFFECT_SIZE="1.0314416149342185" ESTIMABLE="YES" EVENTS_1="1059" EVENTS_2="1038" I2="4.522954881254557" ID="CMP-005.01.01" LOG_CI_END="0.0760501845599442" LOG_CI_START="-0.049160885292125575" LOG_EFFECT_SIZE="0.013444649633909298" NO="1" P_CHI2="0.40117017358332663" P_Z="0.673823914012474" STUDIES="13" TAU2="0.0" TOTAL_1="1779" TOTAL_2="1769" WEIGHT="99.99999999999999" Z="0.4209057409756852">
<NAME>Overall pain response</NAME>
<DICH_DATA CI_END="1.6132727362272175" CI_START="0.8682500745944528" EFFECT_SIZE="1.1835219362438867" ESTIMABLE="YES" EVENTS_1="274" EVENTS_2="257" LOG_CI_END="0.20770779443525414" LOG_CI_START="-0.061355170705414484" LOG_EFFECT_SIZE="0.07317631186491984" ORDER="1948" O_E="0.0" SE="0.15804891760678652" STUDY_ID="STD-BPTWP-1999" TOTAL_1="383" TOTAL_2="378" VAR="0.024979460356676798" WEIGHT="20.22482148481432"/>
<DICH_DATA CI_END="10.53005782365809" CI_START="0.15382961213227972" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="1.0224307560313253" LOG_CI_START="-0.8129600549912993" LOG_EFFECT_SIZE="0.10473535052001297" ORDER="1949" O_E="0.0" SE="1.0781176477257306" STUDY_ID="STD-Cole-1989" TOTAL_1="16" TOTAL_2="13" VAR="1.1623376623376624" WEIGHT="0.416806435064953"/>
<DICH_DATA CI_END="2.468488365572652" CI_START="0.14738558503614393" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.3924310846527731" LOG_CI_START="-0.8315449903263161" LOG_EFFECT_SIZE="-0.21955695283677154" ORDER="1950" O_E="0.0" SE="0.7189696052220029" STUDY_ID="STD-Foro-1998a" TOTAL_1="25" TOTAL_2="25" VAR="0.5169172932330827" WEIGHT="1.3845551942975804"/>
<DICH_DATA CI_END="1.9660130180631947" CI_START="0.09484522250643945" EFFECT_SIZE="0.4318181818181818" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.293586389210406" LOG_CI_START="-1.022984540277123" LOG_EFFECT_SIZE="-0.36469907553335845" ORDER="1951" O_E="0.0" SE="0.7733602811121824" STUDY_ID="STD-Foro-1998b" TOTAL_1="25" TOTAL_2="25" VAR="0.5980861244019138" WEIGHT="1.4504863940260366"/>
<DICH_DATA CI_END="1.8805166861217324" CI_START="0.693087468910556" EFFECT_SIZE="1.1416490486257929" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="99" LOG_CI_END="0.2742771913390838" LOG_CI_START="-0.15921195316876988" LOG_EFFECT_SIZE="0.05753261908515696" ORDER="1952" O_E="0.0" SE="0.2546336692897857" STUDY_ID="STD-Gaze-1997" TOTAL_1="151" TOTAL_2="144" VAR="0.06483830553597995" WEIGHT="7.928506136837234"/>
<DICH_DATA CI_END="6.27865285041419" CI_START="0.0398174586103304" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.7978664713817487" LOG_CI_START="-1.3999264627097112" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1953" O_E="0.0" SE="1.2909944487358056" STUDY_ID="STD-Kagei-1990" TOTAL_1="14" TOTAL_2="13" VAR="1.6666666666666667" WEIGHT="0.4883792572478237"/>
<DICH_DATA CI_END="2.1528898131676213" CI_START="0.31866584134131254" EFFECT_SIZE="0.8282828282828283" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="45" LOG_CI_END="0.33302180281101484" LOG_CI_START="-0.4966644872386813" LOG_EFFECT_SIZE="-0.08182134221383322" ORDER="1954" O_E="0.0" SE="0.4873618337885643" STUDY_ID="STD-Koswig-1999" TOTAL_1="52" TOTAL_2="55" VAR="0.23752155703375216" WEIGHT="2.541740176447494"/>
<DICH_DATA CI_END="1.3892840474773118" CI_START="0.5027181940332073" EFFECT_SIZE="0.8357142857142857" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="56" LOG_CI_END="0.1427910489343491" LOG_CI_START="-0.29867539679850186" LOG_EFFECT_SIZE="-0.07794217393207636" ORDER="1955" O_E="0.0" SE="0.25931957551762697" STUDY_ID="STD-Nielsen-1998" TOTAL_1="122" TOTAL_2="119" VAR="0.06724664224664224" WEIGHT="8.936732466651048"/>
<DICH_DATA CI_END="3.044196600580977" CI_START="0.37709758412264976" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.4834726966498841" LOG_CI_START="-0.42354624989499773" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="1956" O_E="0.0" SE="0.5327874190166598" STUDY_ID="STD-Ozsaran-2001a" TOTAL_1="36" TOTAL_2="38" VAR="0.2838624338624338" WEIGHT="1.871020532834568"/>
<DICH_DATA CI_END="1.9767263624619218" CI_START="0.19489579101794935" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.2959465542413967" LOG_CI_START="-0.7101975398326967" LOG_EFFECT_SIZE="-0.20712549279564998" ORDER="1957" O_E="0.0" SE="0.5910140213527125" STUDY_ID="STD-Ozsaran-2001b" TOTAL_1="36" TOTAL_2="35" VAR="0.3492975734355045" WEIGHT="2.0197233719632712"/>
<DICH_DATA CI_END="1.533787360372059" CI_START="0.5003071992716521" EFFECT_SIZE="0.875993640699523" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.18576515451635767" LOG_CI_START="-0.3007632477033254" LOG_EFFECT_SIZE="-0.05749904659348389" ORDER="1958" O_E="0.0" SE="0.28578919181827434" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="0.08167546216014242" WEIGHT="7.199778581458151"/>
<DICH_DATA CI_END="1.6054826382099332" CI_START="0.988981963873553" EFFECT_SIZE="1.260076732783267" ESTIMABLE="YES" EVENTS_1="392" EVENTS_2="361" LOG_CI_END="0.2056056134401161" LOG_CI_START="-0.004811628586456376" LOG_EFFECT_SIZE="0.10039699242682987" ORDER="1959" O_E="0.0" SE="0.12360012954855515" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.015276992024419615" WEIGHT="32.057170124379816"/>
<DICH_DATA CI_END="0.9725063837496623" CI_START="0.39797483236538495" EFFECT_SIZE="0.6221198156682027" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="63" LOG_CI_END="-0.01210753918667344" LOG_CI_START="-0.4001443915203734" LOG_EFFECT_SIZE="-0.2061259653535234" ORDER="1960" O_E="0.0" SE="0.22793476787421288" STUDY_ID="STD-Warde-2001" TOTAL_1="200" TOTAL_2="198" VAR="0.05195425840587131" WEIGHT="13.480279843977698"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9838848908922833" CI_END="1.3015508585169648" CI_START="0.9412542776311685" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1068379796219558" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="463" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.11446114297289992" LOG_CI_START="-0.02629303708883586" LOG_EFFECT_SIZE="0.04408405294203207" METHOD="MH" NO="2" P_CHI2="0.8108667805858544" P_Q="1.0" P_Z="0.21955321248176907" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1441" TOTAL_2="1435" WEIGHT="100.0" Z="1.2277170883456936">
<NAME>Complete response</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Multiple</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Single</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9838848908922833" CI_END="1.3015508585169648" CI_START="0.9412542776311685" DF="6" EFFECT_SIZE="1.1068379796219558" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="463" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.11446114297289992" LOG_CI_START="-0.02629303708883586" LOG_EFFECT_SIZE="0.04408405294203207" NO="1" P_CHI2="0.8108667805858544" P_Z="0.21955321248176907" STUDIES="7" TAU2="0.0" TOTAL_1="1441" TOTAL_2="1435" WEIGHT="100.0" Z="1.2277170883456936">
<NAME>Complete pain response</NAME>
<DICH_DATA CI_END="1.3922866749206335" CI_START="0.7884338672141332" EFFECT_SIZE="1.0477241847826086" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="192" LOG_CI_END="0.14372866668093734" LOG_CI_START="-0.10323472885186359" LOG_EFFECT_SIZE="0.02024696891453687" ORDER="1961" O_E="0.0" SE="0.1450675210244912" STUDY_ID="STD-BPTWP-1999" TOTAL_1="383" TOTAL_2="378" VAR="0.021044585656191196" WEIGHT="33.38387651941451"/>
<DICH_DATA CI_END="1.6610820311266055" CI_START="0.6284256941417009" EFFECT_SIZE="1.0216979144722982" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="47" LOG_CI_END="0.22039108024546006" LOG_CI_START="-0.20174606647765292" LOG_EFFECT_SIZE="0.009322506883903573" ORDER="1962" O_E="0.0" SE="0.2479654495977337" STUDY_ID="STD-Gaze-1997" TOTAL_1="151" TOTAL_2="144" VAR="0.061486864194206216" WEIGHT="11.571764486848648"/>
<DICH_DATA CI_END="14.61661083165339" CI_START="0.6157378138925208" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="1.164846683993721" LOG_CI_START="-0.21060417455439628" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1963" O_E="0.0" SE="0.8079466429027214" STUDY_ID="STD-Kagei-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.6527777777777777" WEIGHT="0.639219254007509"/>
<DICH_DATA CI_END="2.063698894228519" CI_START="0.4044334519366455" EFFECT_SIZE="0.9135802469135802" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.3146463314655853" LOG_CI_START="-0.39315292976093247" LOG_EFFECT_SIZE="-0.03925329914767358" ORDER="1964" O_E="0.0" SE="0.41576478970730596" STUDY_ID="STD-Koswig-1999" TOTAL_1="52" TOTAL_2="55" VAR="0.17286036036036034" WEIGHT="4.355054543658636"/>
<DICH_DATA CI_END="1.8504507783782647" CI_START="0.3617613045562806" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2672775374381475" LOG_CI_START="-0.44157788887594784" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="1965" O_E="0.0" SE="0.4163851863078505" STUDY_ID="STD-Nielsen-1998" TOTAL_1="122" TOTAL_2="119" VAR="0.17337662337662338" WEIGHT="4.595217251319541"/>
<DICH_DATA CI_END="2.38005904954691" CI_START="0.4747580780063538" EFFECT_SIZE="1.062992125984252" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.3765877320877106" LOG_CI_START="-0.323527637009612" LOG_EFFECT_SIZE="0.026530047539049296" ORDER="1966" O_E="0.0" SE="0.41125123343473724" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="0.16912757700159275" WEIGHT="4.12246479830624"/>
<DICH_DATA CI_END="1.5435050626512972" CI_START="0.9422472881643524" EFFECT_SIZE="1.2059699248120301" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="175" LOG_CI_END="0.18850805829360257" LOG_CI_START="-0.025835103798179514" LOG_EFFECT_SIZE="0.08133647724771152" ORDER="1967" O_E="0.0" SE="0.125906234428477" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.01585237986795861" WEIGHT="41.33240314644492"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.282857162122037" CI_END="4.429648953176821" CI_START="2.672079852582348" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="3.4404034242798147" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="91" I2="36.334697785028126" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.6463693100291364" LOG_CI_START="0.4268494324777939" LOG_EFFECT_SIZE="0.5366093712534652" METHOD="MH" NO="3" P_CHI2="0.17899694956629608" P_Q="1.0" P_Z="9.50551313263711E-22" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1240" TOTAL_2="1236" WEIGHT="99.99999999999999" Z="9.582139468691068">
<NAME>Re-treatment rate</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.15901015996262" CI_START="1.72271205687555" EFFECT_SIZE="2.67671009771987" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="32" LOG_CI_END="0.618989981295521" LOG_CI_START="0.2362126932574301" LOG_EFFECT_SIZE="0.42760133727647553" ORDER="1968" O_E="0.0" SE="0.22484527377170893" STUDY_ID="STD-BPTWP-1999" TOTAL_1="383" TOTAL_2="378" VAR="0.05055539713747474" WEIGHT="36.06918699495937"/>
<DICH_DATA CI_END="199.4407448524292" CI_START="0.47371664235363115" EFFECT_SIZE="9.72" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2998138874606977" LOG_CI_START="-0.32448135760814867" LOG_EFFECT_SIZE="0.9876662649262746" ORDER="1969" O_E="0.0" SE="1.5415240174244111" STUDY_ID="STD-Cole-1989" TOTAL_1="16" TOTAL_2="13" VAR="2.3762962962962964" WEIGHT="0.5633145642165844"/>
<DICH_DATA CI_END="3.932061399227099" CI_START="0.9502519836467019" EFFECT_SIZE="1.9329896907216495" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.5946202907311384" LOG_CI_START="-0.022161215136152986" LOG_EFFECT_SIZE="0.2862295377974928" ORDER="1970" O_E="0.0" SE="0.3623005096641411" STUDY_ID="STD-Nielsen-1998" TOTAL_1="122" TOTAL_2="119" VAR="0.1312616593028964" WEIGHT="15.744010970549228"/>
<DICH_DATA CI_END="13.355310386579086" CI_START="1.397376733284617" EFFECT_SIZE="4.32" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.1256539857764953" LOG_CI_START="0.1453135078533289" LOG_EFFECT_SIZE="0.6354837468149122" ORDER="1971" O_E="0.0" SE="0.575856849495698" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="0.3316111111111111" WEIGHT="4.850764302976144"/>
<DICH_DATA CI_END="6.443305218405791" CI_START="3.082757262291618" EFFECT_SIZE="4.456808943089431" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="41" LOG_CI_END="0.8091087042983582" LOG_CI_START="0.48893932952781005" LOG_EFFECT_SIZE="0.6490240169130841" ORDER="1972" O_E="0.0" SE="0.18806907560418554" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.03536997719861286" WEIGHT="42.772723167298665"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.795933594009485" CI_END="3.1149048726579553" CI_START="1.0576117884969574" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8150372209323058" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" I2="16.596009481942605" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.49344478810255177" LOG_CI_START="0.024326282961010533" LOG_EFFECT_SIZE="0.2588855355317812" METHOD="MH" NO="4" P_CHI2="0.3088842364291067" P_Q="1.0" P_Z="0.03052325999737788" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1240" TOTAL_2="1236" WEIGHT="100.0" Z="2.163233043248048">
<NAME>Pathological fracture rate</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.95763446320934" CI_START="0.7223884927215024" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2293652694285422" LOG_CI_START="-0.14122918072799082" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="1973" O_E="0.0" SE="0.8050939645738956" STUDY_ID="STD-BPTWP-1999" TOTAL_1="383" TOTAL_2="378" VAR="0.648176291793313" WEIGHT="9.689742011176117"/>
<DICH_DATA CI_END="6.737301898904314" CI_START="0.009465065410429853" EFFECT_SIZE="0.25252525252525254" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8284860085506301" LOG_CI_START="-2.0238763804016546" LOG_EFFECT_SIZE="-0.5976951859255123" ORDER="1974" O_E="0.0" SE="1.6754917866921124" STUDY_ID="STD-Cole-1989" TOTAL_1="16" TOTAL_2="13" VAR="2.807272727272727" WEIGHT="7.828752073824613"/>
<DICH_DATA CI_END="3.1101106471931916" CI_START="0.3051160605930676" EFFECT_SIZE="0.9741379310344828" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4927758400270437" LOG_CI_START="-0.5155349315140413" LOG_EFFECT_SIZE="-0.011379545743498752" ORDER="1975" O_E="0.0" SE="0.5922867384220498" STUDY_ID="STD-Nielsen-1998" TOTAL_1="122" TOTAL_2="119" VAR="0.35080358051062965" WEIGHT="28.318564021097256"/>
<DICH_DATA CI_END="8.661996061946029" CI_START="0.014137444101271629" EFFECT_SIZE="0.3499406880189798" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.937617981948026" LOG_CI_START="-1.8496290992411848" LOG_EFFECT_SIZE="-0.4560055586465793" ORDER="1976" O_E="0.0" SE="1.637242732586111" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="2.6805637654060357" WEIGHT="7.1260459054426555"/>
<DICH_DATA CI_END="5.183825445903249" CI_START="1.1638119693191737" EFFECT_SIZE="2.456216216216216" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" LOG_CI_END="0.7146503691824961" LOG_CI_START="0.06588281941740101" LOG_EFFECT_SIZE="0.3902665942999486" ORDER="1977" O_E="0.0" SE="0.38108927018318184" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.14522903184875016" WEIGHT="47.03689598845935"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15277756181923333" CI_END="2.7461100702697374" CI_START="0.721772281084334" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4078587036799002" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.43871794074950965" LOG_CI_START="-0.14159980058528399" LOG_EFFECT_SIZE="0.14855907008211283" METHOD="MH" NO="5" P_CHI2="0.9264559684866455" P_Q="1.0" P_Z="0.31562633817779606" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="1104" WEIGHT="100.0" Z="1.0034862152171309">
<NAME>Spinal 1</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.3158220586634535" CI_START="0.41655522573874554" EFFECT_SIZE="1.4880636604774535" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7255704349806333" LOG_CI_START="-0.38032741287989635" LOG_EFFECT_SIZE="0.17262151105036852" ORDER="1978" O_E="0.0" SE="0.6496098701159102" STUDY_ID="STD-BPTWP-1999" TOTAL_1="383" TOTAL_2="378" VAR="0.42199298335200974" WEIGHT="26.950570346708137"/>
<DICH_DATA CI_END="23.75984887470204" CI_START="0.1910261461208843" EFFECT_SIZE="2.130434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3758436739736464" LOG_CI_START="-0.7189071859518047" LOG_EFFECT_SIZE="0.3284682440109208" ORDER="1979" O_E="0.0" SE="1.2304670243041986" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="1.5140490979000296" WEIGHT="6.516852243291785"/>
<DICH_DATA CI_END="2.999584138395906" CI_START="0.567400174789644" EFFECT_SIZE="1.3045936395759716" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.47706104841335295" LOG_CI_START="-0.2461105347541845" LOG_EFFECT_SIZE="0.11547525682958418" ORDER="1980" O_E="0.0" SE="0.42479456770968177" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.18045042475565543" WEIGHT="66.53257741000009"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07883117363117527" CI_END="2.834344124107575" CI_START="0.7247814101623137" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4332759438279692" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.4524525777844264" LOG_CI_START="-0.13979295435920064" LOG_EFFECT_SIZE="0.15632981171261287" METHOD="MH" NO="6" P_CHI2="0.9613511020405823" P_Q="1.0" P_Z="0.30080498913224074" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="368" WEIGHT="100.0" Z="1.0347086944079913">
<NAME>Spinal 2</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.272012379997417" CI_START="0.3994751758486727" EFFECT_SIZE="1.451219512195122" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7219764214187022" LOG_CI_START="-0.39851020340107407" LOG_EFFECT_SIZE="0.16173310900881405" ORDER="1981" O_E="0.0" SE="0.6581793899173822" STUDY_ID="STD-BPTWP-1999" TOTAL_1="129" TOTAL_2="123" VAR="0.4332001093120175" WEIGHT="27.927117882075507"/>
<DICH_DATA CI_END="22.240086332011103" CI_START="0.17489412746696975" EFFECT_SIZE="1.9722222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3471364687662817" LOG_CI_START="-0.7572247728627055" LOG_EFFECT_SIZE="0.29495584795178803" ORDER="1982" O_E="0.0" SE="1.2361122100890123" STUDY_ID="STD-Price-1986" TOTAL_1="74" TOTAL_2="72" VAR="1.5279733959311423" WEIGHT="7.054093257216533"/>
<DICH_DATA CI_END="3.2088567784554574" CI_START="0.5824359636611776" EFFECT_SIZE="1.3670967741935485" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.5063503335758519" LOG_CI_START="-0.2347518164948457" LOG_EFFECT_SIZE="0.13579925854050312" ORDER="1983" O_E="0.0" SE="0.43532707146633565" STUDY_ID="STD-Steenland-1999" TOTAL_1="168" TOTAL_2="173" VAR="0.1895096591514561" WEIGHT="65.01878886070796"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Evaluable patients (i.e. excluding dropout patients)</NAME>
<DICH_OUTCOME CHI2="11.97080247292838" CI_END="1.0564345683690968" CI_START="0.7597747190437785" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8959086322671336" ESTIMABLE="YES" EVENTS_1="1059" EVENTS_2="1038" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.0238426036351526" LOG_CI_START="-0.11931516137678107" LOG_EFFECT_SIZE="-0.047736278870814206" METHOD="MH" NO="1" P_CHI2="0.44802748043281404" P_Q="1.0" P_Z="0.19117576241874665" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1519" TOTAL_2="1447" WEIGHT="100.0" Z="1.3071088017468966">
<NAME>Overall response</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Multiple</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Single</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.97080247292838" CI_END="1.0564345683690968" CI_START="0.7597747190437785" DF="12" EFFECT_SIZE="0.8959086322671336" ESTIMABLE="YES" EVENTS_1="1059" EVENTS_2="1038" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.0238426036351526" LOG_CI_START="-0.11931516137678107" LOG_EFFECT_SIZE="-0.047736278870814206" NO="1" P_CHI2="0.44802748043281404" P_Z="0.19117576241874665" STUDIES="13" TAU2="0.0" TOTAL_1="1519" TOTAL_2="1447" WEIGHT="100.0" Z="1.3071088017468966">
<NAME>All studies</NAME>
<DICH_DATA CI_END="1.452529350584495" CI_START="0.7033544380617147" EFFECT_SIZE="1.0107635555106371" ESTIMABLE="YES" EVENTS_1="274" EVENTS_2="257" LOG_CI_END="0.16212491673748136" LOG_CI_START="-0.15282576786334648" LOG_EFFECT_SIZE="0.0046495744370674144" ORDER="1984" O_E="0.0" SE="0.1850035911655588" STUDY_ID="STD-BPTWP-1999" TOTAL_1="351" TOTAL_2="330" VAR="0.034226328744153225" WEIGHT="19.434960083097533"/>
<DICH_DATA CI_END="10.53005782365809" CI_START="0.15382961213227972" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="1.0224307560313253" LOG_CI_START="-0.8129600549912993" LOG_EFFECT_SIZE="0.10473535052001297" ORDER="1985" O_E="0.0" SE="1.0781176477257306" STUDY_ID="STD-Cole-1989" TOTAL_1="16" TOTAL_2="13" VAR="1.1623376623376624" WEIGHT="0.5073779615721156"/>
<DICH_DATA CI_END="2.468488365572652" CI_START="0.14738558503614393" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.3924310846527731" LOG_CI_START="-0.8315449903263161" LOG_EFFECT_SIZE="-0.21955695283677154" ORDER="1986" O_E="0.0" SE="0.7189696052220029" STUDY_ID="STD-Foro-1998a" TOTAL_1="25" TOTAL_2="25" VAR="0.5169172932330827" WEIGHT="1.6854173378041004"/>
<DICH_DATA CI_END="1.9660130180631947" CI_START="0.09484522250643945" EFFECT_SIZE="0.4318181818181818" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.293586389210406" LOG_CI_START="-1.022984540277123" LOG_EFFECT_SIZE="-0.36469907553335845" ORDER="1987" O_E="0.0" SE="0.7733602811121824" STUDY_ID="STD-Foro-1998b" TOTAL_1="25" TOTAL_2="25" VAR="0.5980861244019138" WEIGHT="1.7656753062709623"/>
<DICH_DATA CI_END="1.3327934317896548" CI_START="0.29156687398334225" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="99" LOG_CI_END="0.12476284379820327" LOG_CI_START="-0.5352618193919926" LOG_EFFECT_SIZE="-0.20524948779689467" ORDER="1988" O_E="0.0" SE="0.38770175433269616" STUDY_ID="STD-Gaze-1997" TOTAL_1="129" TOTAL_2="111" VAR="0.1503126503126503" WEIGHT="5.7936220987015945"/>
<DICH_DATA CI_END="6.27865285041419" CI_START="0.0398174586103304" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.7978664713817487" LOG_CI_START="-1.3999264627097112" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1989" O_E="0.0" SE="1.2909944487358056" STUDY_ID="STD-Kagei-1990" TOTAL_1="14" TOTAL_2="13" VAR="1.6666666666666667" WEIGHT="0.5945034701249031"/>
<DICH_DATA CI_END="2.1528898131676213" CI_START="0.31866584134131254" EFFECT_SIZE="0.8282828282828283" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="45" LOG_CI_END="0.33302180281101484" LOG_CI_START="-0.4966644872386813" LOG_EFFECT_SIZE="-0.08182134221383322" ORDER="1990" O_E="0.0" SE="0.4873618337885643" STUDY_ID="STD-Koswig-1999" TOTAL_1="52" TOTAL_2="55" VAR="0.23752155703375216" WEIGHT="3.0940571955682747"/>
<DICH_DATA CI_END="1.3369047470950077" CI_START="0.44788619416561126" EFFECT_SIZE="0.7738095238095238" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="56" LOG_CI_END="0.12610046538861672" LOG_CI_START="-0.3488323242266688" LOG_EFFECT_SIZE="-0.11136592941902607" ORDER="1991" O_E="0.0" SE="0.27897787157524306" STUDY_ID="STD-Nielsen-1998" TOTAL_1="106" TOTAL_2="101" VAR="0.07782865282865283" WEIGHT="9.770535291617973"/>
<DICH_DATA CI_END="3.044196600580977" CI_START="0.37709758412264976" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.4834726966498841" LOG_CI_START="-0.42354624989499773" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="1992" O_E="0.0" SE="0.5327874190166598" STUDY_ID="STD-Ozsaran-2001a" TOTAL_1="36" TOTAL_2="38" VAR="0.2838624338624338" WEIGHT="2.277590997032568"/>
<DICH_DATA CI_END="1.9767263624619218" CI_START="0.19489579101794935" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.2959465542413967" LOG_CI_START="-0.7101975398326967" LOG_EFFECT_SIZE="-0.20712549279564998" ORDER="1993" O_E="0.0" SE="0.5910140213527125" STUDY_ID="STD-Ozsaran-2001b" TOTAL_1="36" TOTAL_2="35" VAR="0.3492975734355045" WEIGHT="2.458606780498939"/>
<DICH_DATA CI_END="1.7023471860090686" CI_START="0.26382705127474143" EFFECT_SIZE="0.6701680672268907" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.2310481371770878" LOG_CI_START="-0.5786806765037119" LOG_EFFECT_SIZE="-0.17381626966331204" ORDER="1994" O_E="0.0" SE="0.47563871337837327" STUDY_ID="STD-Price-1986" TOTAL_1="43" TOTAL_2="45" VAR="0.22623218566423434" WEIGHT="3.6176887301350638"/>
<DICH_DATA CI_END="1.5002409088843556" CI_START="0.8830970968445873" EFFECT_SIZE="1.1510249307479223" ESTIMABLE="YES" EVENTS_1="392" EVENTS_2="361" LOG_CI_END="0.17616100372120602" LOG_CI_START="-0.053991542962066985" LOG_EFFECT_SIZE="0.061084730379569525" ORDER="1995" O_E="0.0" SE="0.13519274519523464" STUDY_ID="STD-Steenland-1999" TOTAL_1="542" TOTAL_2="520" VAR="0.018277078353423636" WEIGHT="34.10207935091473"/>
<DICH_DATA CI_END="0.85768408014506" CI_START="0.3234386463068782" EFFECT_SIZE="0.5266955266955267" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="63" LOG_CI_END="-0.06667265098019967" LOG_CI_START="-0.49020808933046445" LOG_EFFECT_SIZE="-0.2784403701553321" ORDER="1996" O_E="0.0" SE="0.24878681302117783" STUDY_ID="STD-Warde-2001" TOTAL_1="144" TOTAL_2="136" VAR="0.061894878333234496" WEIGHT="14.897885396661243"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8915280178494087" CI_END="1.22100118506142" CI_START="0.8713042221566575" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.031437583086004" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="463" I2="0.0" I2_Q="100.0" ID="CMP-006.02" LOG_CI_END="0.08671608545625484" LOG_CI_START="-0.05983018146128223" LOG_EFFECT_SIZE="0.013442951997486314" METHOD="MH" NO="2" P_CHI2="0.6913530077680579" P_Q="0.0" P_Z="0.7191597278027801" Q="1.6244104673690587E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1246" TOTAL_2="1186" WEIGHT="100.0" Z="0.35958202573389403">
<NAME>Complete response</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Multiple</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Single</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8915280178494087" CI_END="1.22100118506142" CI_START="0.8713042221566575" DF="6" EFFECT_SIZE="1.031437583086004" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="463" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.08671608545625484" LOG_CI_START="-0.05983018146128223" LOG_EFFECT_SIZE="0.013442951997486314" NO="1" P_CHI2="0.6913530077680579" P_Z="0.7191597278027801" STUDIES="7" TAU2="0.0" TOTAL_1="1246" TOTAL_2="1186" WEIGHT="100.0" Z="0.35958202573389403">
<NAME>All studies</NAME>
<DICH_DATA CI_END="1.275311614513881" CI_START="0.6943179249391978" EFFECT_SIZE="0.9409950657894737" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="192" LOG_CI_END="0.10561631491012059" LOG_CI_START="-0.1584416225848786" LOG_EFFECT_SIZE="-0.026412653837379" ORDER="1997" O_E="0.0" SE="0.15510893959243385" STUDY_ID="STD-BPTWP-1999" TOTAL_1="351" TOTAL_2="330" VAR="0.024058783141489293" WEIGHT="32.249839486236844"/>
<DICH_DATA CI_END="1.445182173624152" CI_START="0.5139578010053052" EFFECT_SIZE="0.8618367896579585" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="47" LOG_CI_END="0.15992259589044128" LOG_CI_START="-0.2890725377029471" LOG_EFFECT_SIZE="-0.06457497090625292" ORDER="1998" O_E="0.0" SE="0.26374196403451255" STUDY_ID="STD-Gaze-1997" TOTAL_1="129" TOTAL_2="111" VAR="0.06955982359278212" WEIGHT="11.642427983147535"/>
<DICH_DATA CI_END="14.61661083165339" CI_START="0.6157378138925208" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="1.164846683993721" LOG_CI_START="-0.21060417455439628" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1999" O_E="0.0" SE="0.8079466429027214" STUDY_ID="STD-Kagei-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.6527777777777777" WEIGHT="0.6689248504546568"/>
<DICH_DATA CI_END="2.063698894228519" CI_START="0.4044334519366455" EFFECT_SIZE="0.9135802469135802" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.3146463314655853" LOG_CI_START="-0.39315292976093247" LOG_EFFECT_SIZE="-0.03925329914767358" ORDER="2000" O_E="0.0" SE="0.41576478970730596" STUDY_ID="STD-Koswig-1999" TOTAL_1="52" TOTAL_2="55" VAR="0.17286036036036034" WEIGHT="4.557441270854625"/>
<DICH_DATA CI_END="1.809047440975636" CI_START="0.34788785116035204" EFFECT_SIZE="0.7933130699088146" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2574499560714104" LOG_CI_START="-0.458560737294797" LOG_EFFECT_SIZE="-0.10055539061169334" ORDER="2001" O_E="0.0" SE="0.42058822559340436" STUDY_ID="STD-Nielsen-1998" TOTAL_1="106" TOTAL_2="101" VAR="0.1768944555078084" WEIGHT="4.7842668652083065"/>
<DICH_DATA CI_END="2.387901948920743" CI_START="0.3958353691238973" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.37801648999631055" LOG_CI_START="-0.40248540283033385" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="2002" O_E="0.0" SE="0.45847067539305086" STUDY_ID="STD-Price-1986" TOTAL_1="49" TOTAL_2="48" VAR="0.21019536019536023" WEIGHT="3.6308137501482145"/>
<DICH_DATA CI_END="1.4918596011151624" CI_START="0.9021927130830976" EFFECT_SIZE="1.160148637489678" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="175" LOG_CI_END="0.17372795361251248" LOG_CI_START="-0.0447006849755962" LOG_EFFECT_SIZE="0.06451363431845815" ORDER="2003" O_E="0.0" SE="0.12830606354585405" STUDY_ID="STD-Steenland-1999" TOTAL_1="545" TOTAL_2="528" VAR="0.016462445942632742" WEIGHT="42.46628579394982"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.776737643100372" CI_END="4.504433834351784" CI_START="2.7112816514115368" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="3.494680071920076" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="91" I2="30.756765372969195" I2_Q="100.0" ID="CMP-006.03" LOG_CI_END="0.6536402119479784" LOG_CI_START="0.43317463499113457" LOG_EFFECT_SIZE="0.5434074234695565" METHOD="MH" NO="3" P_CHI2="0.21645367402300364" P_Q="0.0" P_Z="4.376390888196809E-22" Q="2.9398398221432297E-30" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1184" TOTAL_2="1185" WEIGHT="100.0" Z="9.6619072567553">
<NAME>Re-treatment</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.325161395164498" CI_START="1.7730782382183154" EFFECT_SIZE="2.769268774703557" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="32" LOG_CI_END="0.6360023179792275" LOG_CI_START="0.24872789954723326" LOG_EFFECT_SIZE="0.44236510876323043" ORDER="2004" O_E="0.0" SE="0.22748691042624222" STUDY_ID="STD-BPTWP-1999" TOTAL_1="329" TOTAL_2="327" VAR="0.051750294415277155" WEIGHT="35.1082544624032"/>
<DICH_DATA CI_END="199.4407448524292" CI_START="0.47371664235363115" EFFECT_SIZE="9.72" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2998138874606977" LOG_CI_START="-0.32448135760814867" LOG_EFFECT_SIZE="0.9876662649262746" ORDER="2005" O_E="0.0" SE="1.5415240174244111" STUDY_ID="STD-Cole-1989" TOTAL_1="16" TOTAL_2="13" VAR="2.3762962962962964" WEIGHT="0.5735362875169464"/>
<DICH_DATA CI_END="4.017198317204359" CI_START="0.9696880898804581" EFFECT_SIZE="1.9736842105263157" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.6039232720955102" LOG_CI_START="-0.013367938545730576" LOG_EFFECT_SIZE="0.29527766677488987" ORDER="2006" O_E="0.0" SE="0.36259991277143827" STUDY_ID="STD-Nielsen-1998" TOTAL_1="120" TOTAL_2="119" VAR="0.13147869674185464" WEIGHT="15.83056142883595"/>
<DICH_DATA CI_END="13.355310386579086" CI_START="1.397376733284617" EFFECT_SIZE="4.32" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.1256539857764953" LOG_CI_START="0.1453135078533289" LOG_EFFECT_SIZE="0.6354837468149122" ORDER="2007" O_E="0.0" SE="0.575856849495698" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="0.3316111111111111" WEIGHT="4.9387846980625945"/>
<DICH_DATA CI_END="6.443305218405791" CI_START="3.082757262291618" EFFECT_SIZE="4.456808943089431" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="41" LOG_CI_END="0.8091087042983582" LOG_CI_START="0.48893932952781005" LOG_EFFECT_SIZE="0.6490240169130841" ORDER="2008" O_E="0.0" SE="0.18806907560418554" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.03536997719861286" WEIGHT="43.548863123181306"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.641076296642719" CI_END="3.1069852069106165" CI_START="1.0538526089055156" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8095039281896008" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" I2="13.813095404323855" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.492339185481436" LOG_CI_START="0.02277987499883868" LOG_EFFECT_SIZE="0.2575595302401373" METHOD="MH" NO="4" P_CHI2="0.3261458026603641" P_Q="1.0" P_Z="0.03154472336460644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1206" TOTAL_2="1188" WEIGHT="100.0" Z="2.1501326536445418">
<NAME>Pathological fracture</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.181438290367122" CI_START="0.6882556252220347" EFFECT_SIZE="3.3372093023255816" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2090171213435155" LOG_CI_START="-0.16225023036266617" LOG_EFFECT_SIZE="0.5233834454904246" ORDER="2009" O_E="0.0" SE="0.8054892302750756" STUDY_ID="STD-BPTWP-1999" TOTAL_1="351" TOTAL_2="330" VAR="0.6488129000891337" WEIGHT="9.910328047611525"/>
<DICH_DATA CI_END="6.737301898904314" CI_START="0.009465065410429853" EFFECT_SIZE="0.25252525252525254" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8284860085506301" LOG_CI_START="-2.0238763804016546" LOG_EFFECT_SIZE="-0.5976951859255123" ORDER="2010" O_E="0.0" SE="1.6754917866921124" STUDY_ID="STD-Cole-1989" TOTAL_1="16" TOTAL_2="13" VAR="2.807272727272727" WEIGHT="7.8317752091373"/>
<DICH_DATA CI_END="3.165465927272748" CI_START="0.3103913008946015" EFFECT_SIZE="0.9912280701754386" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5004376431845888" LOG_CI_START="-0.5080904588906945" LOG_EFFECT_SIZE="-0.003826407853052883" ORDER="2011" O_E="0.0" SE="0.5924143994536414" STUDY_ID="STD-Nielsen-1998" TOTAL_1="120" TOTAL_2="119" VAR="0.3509548206800186" WEIGHT="28.074039395553413"/>
<DICH_DATA CI_END="8.661996061946029" CI_START="0.014137444101271629" EFFECT_SIZE="0.3499406880189798" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.937617981948026" LOG_CI_START="-1.8496290992411848" LOG_EFFECT_SIZE="-0.4560055586465793" ORDER="2012" O_E="0.0" SE="1.637242732586111" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="2.6805637654060357" WEIGHT="7.128797685140546"/>
<DICH_DATA CI_END="5.183825445903249" CI_START="1.1638119693191737" EFFECT_SIZE="2.456216216216216" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" LOG_CI_END="0.7146503691824961" LOG_CI_START="0.06588281941740101" LOG_EFFECT_SIZE="0.3902665942999486" ORDER="2013" O_E="0.0" SE="0.38108927018318184" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.14522903184875016" WEIGHT="47.055059662557206"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1435927690492075" CI_END="2.7098831242844934" CI_START="0.7119421916107147" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3889852880833522" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.43295056040470487" LOG_CI_START="-0.14755526884028072" LOG_EFFECT_SIZE="0.14269764578221203" METHOD="MH" NO="5" P_CHI2="0.9307204005679061" P_Q="1.0" P_Z="0.33525595741931924" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1070" TOTAL_2="1056" WEIGHT="100.0" Z="0.9635811815207728">
<NAME>Spinal 1</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.068245572938263" CI_START="0.39638925950388315" EFFECT_SIZE="1.4173913043478261" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7048576496976228" LOG_CI_START="-0.4018781215969304" LOG_EFFECT_SIZE="0.15148976405034612" ORDER="2014" O_E="0.0" SE="0.6501020704888434" STUDY_ID="STD-BPTWP-1999" TOTAL_1="351" TOTAL_2="330" VAR="0.42263270205388104" WEIGHT="27.393243457599205"/>
<DICH_DATA CI_END="23.75984887470204" CI_START="0.1910261461208843" EFFECT_SIZE="2.130434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3758436739736464" LOG_CI_START="-0.7189071859518047" LOG_EFFECT_SIZE="0.3284682440109208" ORDER="2015" O_E="0.0" SE="1.2304670243041986" STUDY_ID="STD-Price-1986" TOTAL_1="140" TOTAL_2="148" VAR="1.5140490979000296" WEIGHT="6.477360692578145"/>
<DICH_DATA CI_END="2.999584138395906" CI_START="0.567400174789644" EFFECT_SIZE="1.3045936395759716" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.47706104841335295" LOG_CI_START="-0.2461105347541845" LOG_EFFECT_SIZE="0.11547525682958418" ORDER="2016" O_E="0.0" SE="0.42479456770968177" STUDY_ID="STD-Steenland-1999" TOTAL_1="579" TOTAL_2="578" VAR="0.18045042475565543" WEIGHT="66.12939584982266"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07883117363117527" CI_END="2.834344124107575" CI_START="0.7247814101623137" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4332759438279692" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="0.4524525777844264" LOG_CI_START="-0.13979295435920064" LOG_EFFECT_SIZE="0.15632981171261287" METHOD="MH" NO="6" P_CHI2="0.9613511020405823" P_Q="1.0" P_Z="0.30080498913224074" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="368" WEIGHT="100.0" Z="1.0347086944079913">
<NAME>Spinal 2</NAME>
<GROUP_LABEL_1>Single fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Multifraction</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.272012379997417" CI_START="0.3994751758486727" EFFECT_SIZE="1.451219512195122" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7219764214187022" LOG_CI_START="-0.39851020340107407" LOG_EFFECT_SIZE="0.16173310900881405" ORDER="2017" O_E="0.0" SE="0.6581793899173822" STUDY_ID="STD-BPTWP-1999" TOTAL_1="129" TOTAL_2="123" VAR="0.4332001093120175" WEIGHT="27.927117882075507"/>
<DICH_DATA CI_END="22.240086332011103" CI_START="0.17489412746696975" EFFECT_SIZE="1.9722222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3471364687662817" LOG_CI_START="-0.7572247728627055" LOG_EFFECT_SIZE="0.29495584795178803" ORDER="2018" O_E="0.0" SE="1.2361122100890123" STUDY_ID="STD-Price-1986" TOTAL_1="74" TOTAL_2="72" VAR="1.5279733959311423" WEIGHT="7.054093257216533"/>
<DICH_DATA CI_END="3.2088567784554574" CI_START="0.5824359636611776" EFFECT_SIZE="1.3670967741935485" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.5063503335758519" LOG_CI_START="-0.2347518164948457" LOG_EFFECT_SIZE="0.13579925854050312" ORDER="2019" O_E="0.0" SE="0.43532707146633565" STUDY_ID="STD-Steenland-1999" TOTAL_1="168" TOTAL_2="173" VAR="0.1895096591514561" WEIGHT="65.01878886070796"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>